



Volume 174, Issue 14

ISSUE INFORMATION

[Free Access](#)

Issue Information

- Pages: 2157-2158
- First Published:23 June 2017
- [PDF](#)
- [Request permissions](#)

THEMED SECTION: EDITORIAL

[Free Access](#)

Drug metabolism and antibiotic resistance in micro-organisms

- Edith Sim
- Ali Ryan
- Pages: 2159-2160
- First Published:30 April 2017
- [Abstract](#)
- [Full text](#)
- [PDF](#)
- [References](#)
- [Request permissions](#)

THEMED SECTION: REVIEW ARTICLE

[Free Access](#)

Azoreductases in drug metabolism

- Ali Ryan

- Pages: 2161-2173
- First Published:03 August 2016

- [Abstract](#)
- [Full text](#)
- [PDF](#)
- [References](#)
- [Request permissions](#)

THEMED SECTION: RESEARCH PAPERS

[Free Access](#)

Xenobiotic-metabolizing enzymes in *Bacillus anthracis*: molecular and functional analysis of a truncated arylamine *N*-acetyltransferase isozyme

- Xavier Kubiak
- Romain Duval
- Benjamin Pluvinage
- Alain F Chaffotte
- Jean-Marie Dupret
- Fernando Rodrigues-Lima
- Pages: 2174-2182
- First Published:13 October 2016
- [Abstract](#)

- [Full text](#)
- [PDF](#)
- [References](#)
- [Request permissions](#)

Open Access

Identification of the anti-mycobacterial functional properties of piperidinol derivatives

- Collette S Guy
- Esther Tichauer
- Gemma L Kay
- Daniel J Phillips
- Trisha L Bailey
- James Harrison
- Christopher M Furze
- Andrew D Millard
- Matthew I Gibson

- Mark J Pallen

- Elizabeth Fullam

- Pages: 2183-2193

- First Published:14 February 2017

- [Abstract](#)
 - [Full text](#)
 - [PDF](#)
 - [References](#)
 - [Request permissions](#)

THEMED SECTION: REVIEW ARTICLE

[Free Access](#)

Cholesterol metabolism: a potential therapeutic target in *Mycobacteria*

- Areej Abuhammad

- Pages: 2194-2208

- First Published:21 December 2016

- [Abstract](#)
 - [Full text](#)
 - [PDF](#)
 - [References](#)
 - [Request permissions](#)

THEMED SECTION: RESEARCH PAPER

[Free Access](#)

Investigation of the mycobacterial enzyme HsaD as a potential novel target for anti-tubercular agents using a fragment-based drug design approach

- Ali Ryan
- Elena Polycarpou
- Nathan A Lack
- Dimitrios Evangelopoulos
- Christian Sieg
- Alice Halman
- Sanjib Bhakta
- Olga Eleftheriadou
- Timothy D McHugh
- Sebastian Keany
- Edward D Lowe
- Romain Ballet

- [Areej Abuhammad](#)

- [William R Jacobs Jr](#)

- [Alessio Ciulli](#)

- [Edith Sim](#)

- [Pages: 2209-2224](#)

- [First Published:05 April 2017](#)

- [Abstract](#)

- [Full text](#)

- [PDF](#)

- [References](#)

- [Request permissions](#)

THEMED SECTION: REVIEW ARTICLES

[Free Access](#)

Targeting the hard to reach: challenges and novel strategies in the treatment of intracellular bacterial infections

- [Nor Fadhilah Kamaruzzaman](#)

- [Sharon Kendall](#)

- [Liam Good](#)

- [Pages: 2225-2236](#)

- First Published:07 November 2016

- [Abstract](#)
- [Full text](#)
- [PDF](#)
- [References](#)
- [Request permissions](#)

[Free Access](#)

Novel approaches to the treatment of bacterial biofilm infections

- Gareth Hughes
- Mark A Webber
- Pages: 2237-2246

- First Published:07 January 2017

- [Abstract](#)
- [Full text](#)
- [PDF](#)
- [References](#)
- [Request permissions](#)

THEMED SECTION: RESEARCH PAPER

[Free Access](#)

The role of apolipoprotein N-acyl transferase, Lnt, in the lipidation of factor H binding protein of *Neisseria meningitidis* strain MC58 and its potential as a drug target

- R A G da Silva
- C P Churchward

- A V Karlyshev
- O Eleftheriadou
- A K Snabaitis
- M R Longman
- A Ryan
- R Griffin
- Pages: 2247-2260
- First Published:26 October 2016
- [Abstract](#)
- [Full text](#)
- [PDF](#)
- [References](#)
- [Request permissions](#)

RESEARCH PAPERS

[Free Access](#)

Transbody against virus core protein potently inhibits hepadnavirus replication *in vivo*: evidence from a duck model of hepatitis B virus

- Yiping Li
- Zhengwen Liu

- Lingyun Hui
- Xi Liu
- Ai Feng
- Wei Wang
- Lin Zhang
- Na Li
- Guoqing Zhou
- Quanli Wang
- Qunying Han
- Yi Lv
- Quanying Wang

- Guangxiao Yang
- Yawen Wang
- Pages: 2261-2272
- First Published:06 April 2017

- **Abstract**

- **Full text**
- **PDF**
- **References**
- **Request permissions**

Open Access

Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury

- Christoph Reichetzeder
- Karoline von Websky
- Oleg Tsuprykov
- Azadeh Mohagheghi Samarin
- Luise Gabriele Falke

- Ahmed Abdallah Hasan
- Viktoriia Antonenko
- Caterina Curato
- Jörg Rippmann
- Thomas Klein
- Berthold Hocher
- Pages: 2273-2286
- First Published: 18 April 2017
- **Abstract**
 - **Full text**
 - **PDF**
 - **References**
 - **Request permissions**

Free Access

The isoprenoid derivative N⁶-benzyladenosine CM223 exerts antitumor effects in glioma patient-derived primary cells through the mevalonate pathway

- Elena Ciaglia
- Manuela Grimaldi

- Mario Abate
- Mario Scrima
- Manuela Rodriguez
- Chiara Laezza
- Roberta Ranieri
- Simona Pisanti
- Pierangela Ciuffreda
- Clementina Manera
- Patrizia Gazzero
- Anna Maria D'Ursi
- Maurizio Bifulco
- Pages: 2287-2301
- First Published:18 April 2017

- [Abstract](#)
- [Full text](#)
- [PDF](#)
- [References](#)
- [Request permissions](#)

[Free Access](#)

Inhibition of semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 reduces lipopolysaccharide-induced neuroinflammation

• Serena Becchi

• Alberto Buson

• Jonathan Foot

• Wolfgang Jarolimek

• Bernard W Balleine

• Pages: 2302-2317

• First Published:24 April 2017

- [Abstract](#)
- [Full text](#)
- [PDF](#)
- [References](#)
- [Request permissions](#)

[Free Access](#)

Highlight

Factors influencing biased agonism in recombinant cells expressing the human α_{1A} -adrenoceptor

- Edilson Dantas da Silva Junior

- Masaaki Sato

- Jon Merlin

- Natalie Broxton

- Dana S Hutchinson

- Sabatino Ventura

- Bronwyn A Evans

- Roger J Summers

- Pages: 2318-2333

- First Published: 25 April 2017

- **Abstract**

- **Full text**

- **PDF**

- **References**

- **Request permissions**

Free Access

Inhibition of transmembrane member 16A calcium-activated chloride channels by natural flavonoids contributes to flavonoid anticancer effects

- Xuan Zhang
- Honglin Li
- Huiran Zhang
- Yani Liu
- Lifang Huo
- Zhanfeng Jia
- Yucong Xue
- Xiaorun Sun
- Wei Zhang
- Pages: 2334-2345
- First Published: 27 April 2017
- [Abstract](#)
- [Full text](#)
- [PDF](#)
- [References](#)

- [Request permissions](#)

Free Access

ZY15557, a novel, long acting inhibitor of dipeptidyl peptidase-4, for the treatment of Type 2 diabetes mellitus

- Mukul R Jain
- Amit A Johrapurkar
- Samadhan G Kshirsagar
- Vishal J Patel
- Rajesh H Bahekar
- Harilal V Patel
- Pradip A Jadav
- Pankaj R Patel
- Ranjit C Desai
- Pages: 2346-2357

- First Published:27 April 2017

- **Abstract**

- **Full text**

- **PDF**

- **References**

- **Request permissions**

Free Access

Hydroxyeicosapentaenoic acids and epoxyeicosatetraenoic acids attenuate early occurrence of nonalcoholic fatty liver disease

- Chunjong Wang

- Wenli Liu

- Liu Yao

- Xuejiao Zhang

- Xu Zhang

- Chenji Ye

- Hongfeng Jiang

- Jinlong He

- Yi Zhu
- Ding Ai
- Pages: 2358-2372
- First Published:04 May 2017
- **Abstract**
 - **Full text**
 - **PDF**
 - **References**
 - **Request permissions**

[Free Access](#)

ELAC (3,12-di-O-acetyl-8-O-tigloilingol), a plant-derived lathyrane diterpene, induces subventricular zone neural progenitor cell proliferation through PKC β activation

- Maribel Murillo-Carretero
- Noelia Geribaldi-Doldán
- Eugenia Flores-Giubi
- Francisco García-Bernal
- Elkin A Navarro-Quiroz
- Manuel Carrasco

- [Antonio J Macías-Sánchez](#)
- [Pilar Herrero-Foncubierta](#)
- [Antonio Delgado-Ariza](#)
- [Cristina Verástegui](#)
- [Jesús Domínguez-Riscart](#)
- [Mourad Daoubi](#)
- [Rosario Hernández-Galán](#)
- [Carmen Castro](#)
- [Pages: 2373-2392](#)
- [First Published:05 May 2017](#)

Correction(s) for this article

- [Abstract](#)
- [Full text](#)
- [PDF](#)
- [References](#)
- [Request permissions](#)

[Free Access](#)

Mast cells mediate early neutrophil recruitment and exhibit anti-inflammatory properties *via* the formyl peptide receptor 2/lipoxin A₄ receptor

- Ellen L Hughes
- Felix Becker
- Roderick J Flower
- Julia C Buckingham
- Felicity N E Gavins
- Pages: 2393-2408
- First Published:04 May 2017
- [Abstract](#)
- [Full text](#)
- [PDF](#)
- [References](#)
- [Request permissions](#)

Free Access

Design and validation of the first cell-impermeant melatonin receptor agonist

- Florence Gbahou
- Erika Cecon

- Guillaume Viault
- Romain Gerbier
- Frederic Jean-Alphonse
- Angeliki Karamitri
- Gérald Guillaumet
- Philippe Delagrangue
- Robert M Friedlander
- Jean-Pierre Vilardaga
- Franck Suzenet
- Ralf Jockers
- Pages: 2409-2421
- First Published: 10 May 2017
- **Abstract**
- **Full text**
- **PDF**
- **References**

- [Request permissions](#)

COMMENTARY

[Free Access](#)

Does endothelial tetrahydrobiopterin control the endothelial NO synthase coupling state in arterial resistance arteries?


- Thomas Münzel

- Andreas Daiber

- Pages: 2422-2424

- First Published: 21 April 2017

- **[Abstract](#)**
 - **[Full text](#)**
 - **[PDF](#)**
 - **[References](#)**
 - **[Request permissions](#)**



Editorial Board

Editor-in-Chief

A. Johnson, London, UK

Senior Editors

- S. Alexander, Nottingham, UK
C. Beattie, Swindon, UK
A. L. Bonner, Naples, Italy
D. A. Kendall, Nottingham, UK
K. Parrott, Philadelphia, USA
H. Patel, San Diego, USA
C. Sobley, Melbourne, Australia
S. Standford, London, UK
B. Straube, Vancouver, Canada
G. Storch, Reading, UK

US Senior Editor

P. Insel, La Jolla, USA

Asia Senior Editor

X. B. Ning, China

Latin America Senior Editor

M. Tizabi, London, UK

Review/Themed Issue Senior Editor

G. Celis, Apsent, Italy

Consultative Editors and Advisors

Design & Analysis Advisor
M. Curtis, London, UK

Consulting Editor in ARRIVE Guidelines and Animal Welfare
E. Lilley, Apsent, UK

Consulting Editor in Statistical Analysis
P. Stanley, South, UK

Consulting Editor in Clinical Pharmacology
Y. Li, London, UK

Consulting Editor in Radio Chemistry
J. Fukuto, California, USA

Consulting Editor in Medicinal Chemistry & Drug Discovery
M. van der Stek, London, The Netherlands

Press Editors

T. Balfour
A. G. Ramage

Editorial Board

- G. A. J. Smith, London, UK
I. Andriantsaholainaina, Geneva, Switzerland
C. Anticicovic, Oxford, UK
J. Atkinson, Birmingham, UK
S. Bailey, Bath, UK
T. Biró, Budapest, Hungary
E. Borrás, Naples, Italy
D. Brumme, Vancouver, Canada
C. Cabib, California, USA
J. Canales, Melbourne, Australia
H. Carver, Glasgow, UK
M. Carroll, Rome, Italy
S. Chaturvedi, Bangalore, India
M. Ches, London, UK
D. Combes, London, UK
M. Cornejo-Arancibia, Düsseldorf, Germany
F. Curcio, São Paulo, Brazil
M. Dallas, Reading, United Kingdom
M. Decker, Geneva, Switzerland
E. Dorn, Cologne, Ireland
G. Drummond, Clayton, Australia
L. Fattore, Cagliari, Italy
J. Fernandez-Rodríguez, Madrid, Spain
A. P. Ford, San Diego, USA
D. Fulton, Augusta, USA
A. Garland, Sheffield, UK
A. Gibb, London, UK
J. Gibbins, Reading, UK
M. Giles, Auckland, New Zealand
R. Gokhale, Mumbai, India
E. Grant, California, USA
K. Gregory, Melbourne, Australia
C. Gruber, Vienna, Austria
D. Hall, Swindon, UK
H. Han, Nanyang, China
S. Harner, Bristol, UK
H. L. Hay, Auckland, New Zealand
A. Hill, Dordrecht, Australia
S. Hogg, Adelaide, Canada
Y. Huang, Hong Kong, China
N. Hyatt, Cork, Ireland
Z. Jeffrey, Sheffield, UK
M. Jimenez, Barcelona, Spain
S. Kato, Fukuoka, Japan
M. Kashefi, Sydney, Australia
B. Kemp-Harner, Victoria, Australia
M. Kosa, Nottingham, UK
R. Lane, Nottingham, UK
J. Liu, Shanghai, China
C. Loughrey, Glasgow, UK
K. MacLeod, London, UK
P. Maffei, Glasgow, UK
K. Maitland, California, USA
C. Mann, Birmingham, UK
P. McCormick, London, UK
L. McGrath, Sydney, Australia
A. Mitchell, Lund, Sweden
G. Mirza, Nottingham, UK
M. A. Moro, Madrid, Spain
S. Murbel, Bristol, UK
R. Myers, Glasgow, UK
S. Natcha, Cambridge, UK
R. Ostrom, California, USA
P. Pacher, Maryland, USA
H. Patel, San Diego, USA
J. Pang, Dallas, China
S. Palsbø, Montreal, Canada
M. Roberts, Queensland, Australia
E. Rossi, Catanzaro, Italy
G. Schultz, Stockholm, Sweden
A. Shukla, Bangalore, India
P. Shukla, Rio de Janeiro, Brazil
K. Staronowicz, Arnhem, Poland
C. Stead, Adelaide, Australia
P. Tammarit, Oxford, UK
I. Tildesley, Athens, Greece
J. Tronzo, Aveiro, Portugal
S. Tucker, Aberdeen, UK
V. Vadys, Mumbai, India
M. Van der Gevel, Utrecht, The Netherlands
I. Vocke, Melbourne, Australia
S. Vokonas, Milan, Italy
R. Vlahos, Victoria, Australia
S. Wines, Kingston, USA
B. Winkler, Aachen, Germany
U. Winkler, Hamburg, Germany
S. Wray, Leeds, UK
J. Whitham, London, UK
D. Wootton, Victoria, Australia
Y. Xiang, California, USA
R. Xiang, Harbin, China
B. Xie, Hong Kong, China
U. Yokoyama, Tokyo, Japan

Reviews Board

- P. Beal, Melbourne, Australia
T. Blackburn, Leigh-on-Sea, UK
M. Christie, Sydney, Australia
J. Hancher, Bristol, UK
D. Hoey, Melbourne, Australia
H. Kamao, Tokyo, Japan
C. Laramie, Victoria, Australia
A. L. Lister, Melbourne, Australia
D. MacKenzie, Liverpool, UK
M. Muscarà, São Paulo, Brazil
P. Nave, Budapest, Hungary
A. Naves de Abreu, Toulouse, France
E. H. Ozols, Pennsylvania, USA
M. Parake, Jersey City, USA
A. Papadimitrakou, Athens, Greece
S. Verrill, Toulouse, France
S. Wormald, Perth, UK

Associate Managing Editor

Alice Kullaway

BJP@bpc.wiley.com

Submit an article

Get Content alerts

Subscribe to this journal



Journal Features

- Reviews
Mini-Reviews
JOPHAR Reviews
Reviews Series
Themed Issues
Image Bank
Concise Guide to PHARMACOLOGY
Guide to PHARMACOLOGY

Prizes & Awards

The BJP Editors' Performance Awards

RJP Prize for Early Career Researchers

Journal Resources

- Call for Papers
Ethics Policy
RJP Policy Editorials
Declaration of Transparency and Scientific Rigour
HOW to link to the Guide to PHARMACOLOGY
For Chinese Authors
For North American Authors
For Latin American Authors
Open Access
Author Services
Editors Toolkit





Evidence Based Nursing Paper

Join Leading Researchers in the Field and Publish With
Submit Your Manuscript.

Hindawi

British Journal of Pharmacology

COUNTRY	SUBJECT AREA AND CATEGORY	PUBLISHER	H-INDEX
United States  Universities and research institutions in United States	Pharmacology, Toxicology and Pharmaceutics Pharmacology	Wiley-Blackwell	202
PUBLICATION TYPE	ISSN	COVERAGE	INFORMATION
Journals	14765381, 00071188	1965-2020	Homepage How to publish in this journal BJPedoffice@wiley.com

Call For Papers Elsevier Q4

Peer Reviewed Indexed Journal

Collaboration proposals are invited to provide a single platform for worldwide research.

turcomat.org

OPEN

SCOPE

The British Journal of Pharmacology (BJP) is a broad-based journal giving leading international coverage of all aspects of experimental pharmacology. Its scope includes: - Anti-infective drugs - Biopharmaceuticals - Cancer pharmacology - Cardiovascular pharmacology - Drug discovery - Drug safety & toxicology - Endocrine & metabolic pharmacology - Gastrointestinal pharmacology - Genitourinary & renal pharmacology - Immunopharmacology & Inflammation - Molecular & cellular mechanisms - Neuropharmacology - Pharmacokinetics & drug metabolism - Respiratory system pharmacology - Methods & techniques - Social impact of pharmacology

 Join the conversation about this journal

Call For Papers Elsevier Q4

Collaboration proposals are invited to provide a single platform for worldwide research.

turcomat.org


OPEN

RESEARCH PAPER

Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury

Correspondence Professor Berthold Hocher, Institute of Nutritional Science, University of Potsdam, Arthur-Scheunert-Allee 114-116, 14558 Nuthetal, Potsdam, Germany. E-mail: hocher@uni-potsdam.de

Received 25 July 2016; **Revised** 2 April 2017; **Accepted** 5 April 2017

Christoph Reichtzeder^{1,2} , Karoline von Websky^{1,2}, Oleg Tsuprykov^{1,2,9}, Azadeh Mohagheghi Samarin^{1,3}, Luise Gabriele Falke², Sulisty Emantoko Dwi Putra^{1,6}, Ahmed Abdallah Hasan^{1,7}, Viktoriia Antonenko^{1,2}, Caterina Curato^{4,5}, Jörg Rippmann⁸, Thomas Klein⁸ and Berthold Hocher^{1,9,10}

¹Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany, ²Center for Cardiovascular Research, Charité – Universitätsmedizin Berlin, Berlin, Germany, ³Institute of Aquaculture, University of South Bohemia, České Budějovice, Czech Republic, ⁴German Rheumatism Research Center (DREZ), Berlin, Germany, ⁵Cluster of Excellence NeuroCure, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁶Faculty of Biotechnology, University of Surabaya, Surabaya, Indonesia, ⁷Department of Biochemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt, ⁸Cardio Metabolic Diseases, Boehringer-Ingelheim Pharma GmbH&Co KG, Biberach, Germany, ⁹Institut für Laboratoriumsmedizin, Berlin, Germany, and ¹⁰Department of Basic Medicine, Medical College of Hunan Normal University, Changsha, China

BACKGROUND AND PURPOSE

Results regarding protective effects of dipeptidyl peptidase 4 (DPP4) inhibitors in renal ischaemia–reperfusion injury (IRI) are conflicting. Here we have compared structurally unrelated DPP4 inhibitors in a model of renal IRI.

EXPERIMENTAL APPROACH

IRI was induced in uninephrectomized male rats by renal artery clamping for 30 min. The sham group was uninephrectomized but not subjected to IRI. DPP4 inhibitors or vehicle were given p.o. once daily on three consecutive days prior to IRI: linagliptin (1.5 mg·kg⁻¹·day⁻¹), vildagliptin (8 mg·kg⁻¹·day⁻¹) and sitagliptin (30 mg·kg⁻¹·day⁻¹). An additional group received sitagliptin until study end (before IRI: 30 mg·kg⁻¹·day⁻¹; after IRI: 15 mg·kg⁻¹·day⁻¹).

KEY RESULTS

Plasma-active glucagon-like peptide type 1 (GLP-1) increased threefold to fourfold in all DPP4 inhibitor groups 24 h after IRI. Plasma cystatin C, a marker of GFR, peaked 48 h after IRI. Compared with the placebo group, DPP4 inhibition did not reduce increased plasma cystatin C levels. DPP4 inhibitors ameliorated histopathologically assessed tubular damage with varying degrees of drug-specific efficacies. Renal osteopontin expression was uniformly reduced by all DPP4 inhibitors. IRI-related increased renal cytokine expression was not decreased by DPP4 inhibition. Renal DPP4 activity at study end was significantly inhibited in the linagliptin group, but only numerically reduced in the prolonged/dose-adjusted sitagliptin group. Active GLP-1 plasma levels at study end were increased only in the prolonged/dose-adjusted sitagliptin treatment group.

CONCLUSIONS AND IMPLICATIONS

In rats with renal IRI, DPP4 inhibition did not alter plasma cystatin C, a marker of glomerular function, but may protect against tubular damage.

Abbreviations

AKI, acute kidney injury; CKD, chronic kidney disease; DPP4, dipeptidyl peptidase 4; ESRD, end-stage renal disease; GIP, gastric inhibitory polypeptide; GLP-1, glucagon-like peptide type 1; IRI, ischaemia reperfusion injury; KC, keratinocyte chemoattractant; MCP-1, monocyte chemotactic protein 1; UniNX, uni-nephrectomy

Introduction

Acute kidney injury (AKI) is a frequent and increasingly prevalent syndrome, defined by a rapid deterioration of kidney function (Kam Tao Li *et al.*, 2013; Kramann *et al.*, 2015), which is associated with high morbidity and mortality (Lafrance and Miller, 2010; Kam Tao Li *et al.*, 2013). The incidence of AKI is increasing and expected to double over the next 10 years (Silver *et al.*, 2015). Data from recent observational studies suggest an association between AKI and chronic kidney disease (CKD) and end-stage renal disease (ESRD) (Coca *et al.*, 2012). About 14% of patients with AKI progress to stage 4 CKD, and more severe cases of AKI are associated with a higher risk for progression into CKD (Chawla *et al.*, 2011; Coca *et al.*, 2012). The high incidence of AKI is discussed as one possible explanation for the increasing burden of CKD and ESRD (Coca *et al.*, 2012; Belayev and Palevsky, 2014). There are many risk factors and causes for AKI (Hsu *et al.*, 2008; Basile *et al.*, 2012). Among these, the most prominent aetiology of AKI is acute tubular necrosis as a consequence of an ischaemic or nephrotoxic insult (Basile *et al.*, 2012; Kramann *et al.*, 2015). In a clinical setting, kidney hypoxia or ischaemia–reperfusion injury (IRI) inevitably occurs during surgery involving renal or aortic vascular occlusion. Of all cases of hospital-acquired AKI, approximately 30–40% occur during surgery, making the perioperative period one of the leading causes of AKI (Uchino *et al.*, 2005; Thakar *et al.*, 2009). The most vulnerable renal tissue with regards to both ischaemic and toxic insults are tubular epithelial cells (Bonventre and Yang, 2011; Kramann *et al.*, 2015). These cells rely on aerobic respiration and have a high metabolic demand due to their involvement in fluid and electrolyte reabsorption, making them uniquely susceptible to IRI (Uchida and Endou, 1988; Kramann *et al.*, 2015).

Dipeptidyl peptidase 4 (DPP4) inhibitors are a new drug class approved for the treatment of type 2 diabetes. Its anti-diabetic effects are elicited by an inhibition of the ubiquitously expressed serine exopeptidase DPP4, which mediates the degradation of incretins such as **glucagon-like peptide 1 (GLP-1)** and **gastric inhibitory polypeptide (GIP)** (Mentlein, 1999). Moreover, DPP4 also has several other substrates, including growth factors, neuro- and vasoactive peptides and chemokines (Mentlein, 1999). Based on the structure, DPP4 inhibitors can be broadly divided into peptidomimetics (e.g. **vildagliptin**) and non-peptidomimetics (e.g. **linagliptin**, **sitagliptin**) (Baetta and Corsini, 2011; Ceriello *et al.*, 2014). Although their chemical structures are different, all DPP4 inhibitors are substrate competitive active site binders but show different binding characteristics on the DPP4 protein (Schnapp *et al.*, 2016).

Preclinical evidence suggests that DPP4 inhibitors have protective effects on IRI of the heart and lungs (Sauvé *et al.*, 2010; Jungraithmayr *et al.*, 2012; Hocher *et al.*, 2013). As DPP4 is strongly expressed in the kidney (Mentlein, 1999), DPP4 inhibition might also elicit protective effects in renal IRI. Several studies already investigated putative protective effects in renal IRI, but with conflicting results. Therefore, we studied the effects of three structurally different DPP4 inhibitors - linagliptin, vildagliptin and sitagliptin - on the

outcome of IR-induced AKI in uni-nephrectomized rats. One additional arm (sitagliptin) was treated throughout the entire experiment and dose adjusted.

Methods

Animals

All animal care and experimental procedures were approved by the Committee on the Ethics of Animal Experiments (Landesamt fuer Gesundheit und Soziales), Berlin, Germany. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny *et al.*, 2010; Kilkenny *et al.*, 2012; McGrath & Lilley, 2015). Male Wistar rats (10 sham animals, 14 placebo-treated animals and 14 per each treatment group), aged 5–6 weeks, weighing 200–250 g, were obtained from Charles River, Germany, and housed in groups under standardized specific pathogen-free conditions (12 h light/dark cycle, 23°C, humidity of 50–60%, rat type IV cages) with food and water *ad libitum*. After an acclimatization period of 1 week, all animals were subjected to uni-nephrectomy. Two weeks later, the remaining kidney was exposed to IRI by clamping the renal artery for 30 min, and sham surgery was performed without clamping. Animals were randomly allocated to six different groups: sham, placebo, linagliptin (1.5 mg·kg⁻¹·day⁻¹), vildagliptin (8 mg·kg⁻¹·day⁻¹), sitagliptin (30 mg·kg⁻¹·day⁻¹) and prolonged/dose-adjusted sitagliptin, a group which was treated with sitagliptin until the end of study in order to block the DPP4 activity during the entire experiment. In this group, treatment started with 30 mg·kg⁻¹ once daily on two consecutive days prior to IRI; after that, the dose was adjusted to 15 mg·kg⁻¹·day⁻¹ because of renal failure. All groups received DPP4 inhibitor treatment or vehicle *via* gavage once daily on two consecutive days prior to IRI and on the day of surgery 2 h before IRI. Doses in the current study were selected based on previous DPP4 inhibitor studies in similar settings and calculated on AUC (Chaykovska *et al.*, 2011; Connelly *et al.*, 2014).

Baseline blood samples were taken from the tail vein. Blood samples were collected at baseline 24 h before IRI, and 24, 48, 72 h and 1 week (168 h) after IRI. Afterwards, animals were killed under deep isoflurane anaesthesia and organs were harvested. Two sham animals were excluded from the study because of critical weight loss occurring shortly after the surgical sham intervention (probably due to infection), reducing the *n*-value of the sham group to eight. The *n*-value variation of measured plasma parameters among the analysed experimental groups originated from either limited plasma sample volume or from plasma samples that gave a NaN (not a number) result in the respective assay. The *n*-value variation of histological readouts among the experimental groups occurred because of suboptimal tissue processing in one batch of samples due to technical difficulties of the automated tissue processor. The whole animal experiment was performed in a randomized fashion using six arms. Rats were randomly allocated to six different arms, with each arm containing about the same number of animals from every treatment group. The animal study was performed by different investigators than the following experiments, ensuring that all analyses were performed in a blinded fashion.

Biomarkers of renal function and injury

Plasma cystatin C, a biomarker of glomerular filtration rate and **osteopontin**, a biomarker of tubular damage, were measured by automated immunoassays (Myriad RBM, Inc., Austin, Texas, USA).

DPP4 activity and GLP-1 measurements

Whole blood was collected into lithium heparin-treated tubes and plasma was separated by centrifugation. Activity of plasma DPP4 was assessed using a previously reported method (Chaykovska *et al.*, 2011). A 20 μL volume of plasma was diluted with 30 μL of DPP4 assay buffer (100 $\text{mmol}\cdot\text{L}^{-1}$ Tris, 100 $\text{mmol}\cdot\text{L}^{-1}$ NaCl, adjusted to pH 7.8 with HCl) and mixed with 50 μL substrate (final concentration 100 $\text{mmol}\cdot\text{L}^{-1}$ H-Ala-Pro-7-amido-4-trifluoromethylcoumarin). After incubation at room temperature for 10 min, fluorescence of the wells was determined using a Wallac Victor 1420 Multilabel Counter at an excitation wavelength of 405 nm and an emission wavelength of 535 nm. Active (uncleaved, 7–36 amide or 7–37) GLP-1 was detected in plasma samples using a commercially available multiarray assay system (K150JWC from Meso Scale Discovery, Rockwell, Maryland, USA) following the instructions provided by the supplier. This antibody only detects active GLP-1 (7–36 amide or 7–37 GLP-1) but not cleaved and inactive GLP-1 (9–36 amide or 9–37 GLP-1).

Cytokine detection from plasma and kidney homogenates

For preparation of kidney extracts, 50 mg of tissue was lysed in 500 μL of Meso Scale Discovery (Gaithersburg, MD, USA) lysis buffer (MSD R60TX-2) with protease inhibitor cocktails from Thermo Fisher, Germany (1861278), and Sigma, Germany (P5726), using FastPrep devices (MP Biomedicals) at 4°C, 30 s, 6000 \times g. Homogenates were centrifuged for 10 min, 4°C at 10 000 \times g. Supernatants were adjusted to protein concentration of 20 $\text{mg}\cdot\text{mL}^{-1}$ and used for cytokine analysis and DPP4 activity measurements.

Cytokine concentrations of kidney tissue (50 μL of lysate) and plasma samples (undiluted sample) were analysed by Meso Scale Discovery (Gaithersburg, MD, USA) immunoassays according to the manufacturer's protocols using a MSD Custom Rat Cytokine kit (K153A0H-2). Concentrations of CCL2 were analysed in 25 μL aliquots by the Rat Mcp-1 Ultra Sensitive Kit (K153AYC-2). Absolute concentrations were calculated by comparison with a series of standard dilutions of the respective cytokine measured on the same plate. In both plasma and renal homogenates, concentrations of **CCL2**, **IFN- γ** , **IL-10**, **IL-13**, **IL-1 β** , **IL-4**, **IL-5**, **IL-6**, **keratinocyte chemoattractant (KC)** and **TNF- α** were analysed.

Renal DPP4 activity

For DPP4 activity, 2 μL of kidney homogenate extracts were diluted with 130 μL of HEPES buffer (10 mM) pH 7.6 and incubated for 10 min at 37°C in 96-well plates. A total of 100 μL of Gly-Pro-pNA (4-nitroaniline, Sigma Aldrich, Germany) was added as DPP4 substrate (1 mM solution) and kinetics (20 min, every 60 s) were detected at 405 nm. The reaction was observed to be linear up until 11 min; thus, this timeframe was used to assess renal DPP4 activity.

Because Gly-Pro-pNA is an artificial DPP4 substrate and high protease activity is present in the kidney, we added 10 μM sitagliptin to a parallel set of extracts, to define DPP4-specific activity baseline. Values were given as specific DPP4 activity in (δ OD405 $\text{nm}\cdot\text{min}^{-1}$) by subtracting sitagliptin-inhibited baseline. For graphic display and statistical analysis, treatment group-specific AUC of the linear kinetic period (0–11 min) were calculated (minutes were converted to seconds).

Histological assessment of kidney tubular necrosis and tubular dilatation

For pathohistological evaluation, all samples were embedded in paraffin, cut in 3 μm sections and stained with haematoxylin–eosin. Tubular dilatation and tubular necrosis were analysed using a semiquantitative grading score on haematoxylin–eosin stained kidney samples by two blinded independent investigators. At least 25 viewing fields of the outer medulla were randomly chosen with 200 \times magnification per each kidney sample. Tubular dilatation was assessed by a three-point scoring system, where 1 indicates <25% tubules show dilation and thinned epithelium, 2 indicates 25 to 50% tubules show dilation and thinned epithelium, and 3 indicates >50% tubules show dilation and thinned epithelium (Blydt-Hansen *et al.*, 2003). Tubular necrosis was classified according to a 1–5 score as follows: grade 1 (no to mild damage) = less than 10% tubular necrosis, grade 2 (mild to moderate damage) = 10 to 25% tubular cell necrosis, grade 3 (moderate to severe damage) = 25 to 50% tubular cell necrosis, grade 4 (severe damage) = 50 to 75% and grade 5 (severe to very severe) = greater than 75% tubular cell necrosis (Park *et al.*, 2008).

Western blot analysis of renal protein expression

Western blots were performed as previously described (Putra *et al.*, 2014). Briefly, renal samples containing both cortex and medulla were crushed in a metal mortar after cooling in liquid nitrogen. Protein was extracted using a urea/thiourea buffer [2 M thiourea, 7 M urea, 2% SDS, 1% DTT and protease inhibitor (Complete Mini, Cat. no.: 11 697 498 001, Roche)]. Protein extracts were separated by SDS-PAGE employing a 10% polyacrylamide gel. Following SDS-PAGE gels were blotted to nitrocellulose membrane (AmershamTM HybondTM ECL, GE Healthcare) using a Biorad Trans-Blot semidry blotter and transfer buffer (184 mM glycine, 24 mM Tris, 20% methanol). The anti-osteopontin antibody (sc-21742, Santa Cruz Biotechnology) was used at a dilution of 1:1000 and the anti-housekeeping protein actin antibody (A5060, Sigma-Aldrich) at a dilution of 1:10 000. The signals were developed using enhanced chemiluminescence. The developed membranes were digitalized using a 600 dpi scanner resolution and analysed with AlphaEaseFCTM.

Statistical analysis

The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis *et al.*, 2015). Statistical analyses were performed using SPSS Version 20 and Graph Pad Prism 6.

Quantitative data in text and tables are expressed as mean \pm SD. In the figures, data are presented as means \pm SEM. Data were analysed for normal distribution using the Kolmogorov–Smirnov test. Not normally distributed data were analysed using the Kruskal–Wallis test followed by a Dunn *post hoc* test. For normally distributed data, group comparisons were performed employing one-way ANOVA. Heterogeneity of variance was assessed using Levene's test. If results of the test were significant ($P < 0.05$), Welch's F was used. According to heterogeneity of variances, either a Bonferroni (equal variances assumed) or a Games–Howell (unequal variances assumed) *post hoc* test was used, as recommended (Field, 2013; Muth, 2014). *Post hoc* tests were only run if F achieved $P < 0.05$. For the comparison of parameters measured over time, two-way ANOVA was used followed by a Bonferroni *post hoc* test. To analyse if two parameters are correlated, Pearson bivariate correlation analysis was employed. P values lower than 0.05 were considered statistically significant.

Materials

Linagliptin [BI1356; 8-[(3R)-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4-methyl-quinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione] was developed and synthesized by Boehringer Ingelheim Pharma GmbH and Co. KG (Biberach an der Riss, Germany), and vildagliptin [(2S)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile] and sitagliptin [(3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one] were from Sequoia, Oxford, UK. The compounds were dissolved in 0.5% Natrosol, and were administered *p.o.*

Nomenclature of targets and ligands

Key protein targets and ligands in this article are hyperlinked to corresponding entries in <http://www.guidetopharmacology.org>, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan *et al.*, 2016), and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander *et al.*, 2015).

Table 1

Basic animal characteristics and summary of kidney parameters

	Sham (8)	Placebo (14)	Linagliptin (14)	Vildagliptin (14)	Sitagliptin (14)	Prolonged/dose-adjusted sitagliptin (14)
Baseline weight (g)	335.1 \pm 10.7	333.1 \pm 32.8	327.3 \pm 24.1	327.1 \pm 30.8	337.1 \pm 21.6	321.3 \pm 27.3
Final Weight (g)	362.4 \pm 15.9	345.3 \pm 26.4	344.9 \pm 21.9	343.7 \pm 28.0	351.6 \pm 21.6	334.0 \pm 28.8
Kidney Weight (g)	1.7 \pm 0.2*	2.5 \pm 0.7	2.3 \pm 0.2	2.5 \pm 0.5	2.4 \pm 0.5	2.2 \pm 0.3
Rel. Kidney Weight (g·g ⁻¹ BW \times 100)	0.46 \pm 0.04*	0.72 \pm 0.17	0.66 \pm 0.10	0.74 \pm 0.12	0.68 \pm 0.12	0.66 \pm 0.12
Tubular dilatation score	1.1 \pm 0.16*	2.8 \pm 0.17	2.4 \pm 0.41	2.8 \pm 0.26	2.3 \pm 0.46*	2.0 \pm 0.52*
Tubular necrosis score	1.2 \pm 0.15*	4.5 \pm 0.48	4.0 \pm 0.78	4.5 \pm 0.62	3.6 \pm 0.94	3.0 \pm 1.03*
Renal osteopontin expression	0.75 \pm 0.41*	1.17 \pm 0.43	0.68 \pm 0.22*	0.70 \pm 0.34*	0.76 \pm 0.34*	0.67 \pm 0.29*

* $P < 0.05$, significantly different from placebo; one-way ANOVA. Values displayed are means \pm SD.

Results

Basic characteristics of the treatment groups are displayed in Table 1. There were no statistical significant differences regarding baseline and final body weight.

Kidney function

The impact of IRI on kidney function was assessed by plasma cystatin C and osteopontin levels. IRI induced steadily increasing plasma cystatin C concentrations, which peaked 48 h after clamping. The placebo group displayed significantly higher cystatin C levels 48 h after IRI compared with the sham group (Figure 1A). Treatment with DPP4 inhibitors did not significantly affect plasma cystatin C concentrations compared with placebo at any point (Figure 1A). Furthermore, IRI induced an increase in plasma osteopontin levels, which peaked 72 h after clamping (Figure 1B). Compared with the sham group, the placebo group displayed significantly elevated plasma osteopontin levels at 24 h, 48 h and 72 h after clamping (Figure 1B). Treatment with DPP4 inhibitors resulted in numerically lower plasma osteopontin concentrations compared with the placebo group, but these differences did not reach statistical significance at any point (Figure 1B).

DPP4 activity and active GLP-1 levels in plasma

All groups with DPP4 inhibitor treatment displayed a significantly reduced DPP4 activity 24 h after induction of IRI compared with the placebo group (Figure 2A). Plasma concentrations of active GLP-1 were significantly increased in all DPP4 inhibitor treatment groups versus the placebo group, up to 24 h after IRI (Figure 2B). At the end of the study, 168 h after IRI, active GLP-1 plasma concentrations of all treatment groups except the prolonged/dose-adjusted sitagliptin group returned to baseline. The prolonged/dose-adjusted sitagliptin group, as expected, still displayed significantly elevated active GLP-1 plasma levels (Figure 2C).




Figure 1

Concentrations of plasma cystatin C and osteopontin over the course of the study. (A) Plasma cystatin C concentrations; *n*-values: sham (0 h: *n* = 8; 24 h: *n* = 8; 48 h: *n* = 8; 72 h: *n* = 8; 168 h: *n* = 8), placebo (0 h: *n* = 12; 24 h: *n* = 14; 48 h: *n* = 14; 72 h: *n* = 14; 168 h: *n* = 14), linagliptin (0 h: *n* = 14; 24 h: *n* = 14; 48 h: *n* = 14; 72 h: *n* = 13; 168 h: *n* = 14), vildagliptin (0 h: *n* = 14; 24 h: *n* = 14; 48 h: *n* = 14; 72 h: *n* = 14; 168 h: *n* = 14), sitagliptin (0 h: *n* = 14; 24 h: *n* = 14; 48 h: *n* = 14; 72 h: *n* = 14; 168 h: *n* = 13), prolonged/dose-adjusted sitagliptin (0 h: *n* = 14; 24 h: *n* = 14; 48 h: *n* = 14; 72 h: *n* = 14; 168 h: *n* = 14). Values shown are means \pm SEM. **P* < 0.05, significantly different as indicated; two-way ANOVA. (B) Plasma osteopontin concentrations; *n*-values: sham (0 h: *n* = 8; 24 h: *n* = 8; 48 h: *n* = 8; 72 h: *n* = 8; 168 h: *n* = 8), placebo (0 h: *n* = 12; 24 h: *n* = 14; 48 h: *n* = 14; 72 h: *n* = 14; 168 h: *n* = 14), linagliptin (0 h: *n* = 14; 24 h: *n* = 14; 48 h: *n* = 14; 72 h: *n* = 13; 168 h: *n* = 14), vildagliptin (0 h: *n* = 14; 24 h: *n* = 14; 48 h: *n* = 14; 72 h: *n* = 14; 168 h: *n* = 14), sitagliptin (0 h: *n* = 14; 24 h: *n* = 14; 48 h: *n* = 14; 72 h: *n* = 14; 168 h: *n* = 13), prolonged/dose-adjusted sitagliptin (0 h: *n* = 14; 24 h: *n* = 14; 48 h: *n* = 14; 72 h: *n* = 14; 168 h: *n* = 14). Values shown are means \pm SEM. **P* < 0.05, significantly different as indicated; two-way ANOVA.

Renal DPP4 activity

The AUC of renal DPP4 activity, assessed 168 h after IRI, was not significantly different between the sham and placebo group. Kidney homogenates of linagliptin-treated animals still displayed a significantly reduced DPP4 activity compared with placebo-treated animals. Also renal DPP4 activity of prolonged/dose-adjusted sitagliptin-treated animals was numerically reduced, but did not reach statistical significance. Vildagliptin- and sitagliptin-treated animals displayed no reduction of renal DPP4 activity (Figure 3).

Kidney morphology

Kidney weight, both absolute and in relation to body weight, was significantly increased in the placebo group compared with the sham group (Table 1). IRI caused a significant increase of the tubular necrosis and tubular dilatation score

in the placebo group compared with the sham group (Table 1; Figure 4B). The prolonged/dose-adjusted treatment with sitagliptin led to a significant decrease of both tubular necrosis and dilatation. Regular sitagliptin treatment significantly reduced tubular dilatation, but only numerically affected tubular necrosis score. Also linagliptin treatment resulted in a non-significant, numerically decreased tubular necrosis and dilatation score, whereas vildagliptin treatment was without effect (Table 1; Figure 4C).

Furthermore, to assess the validity of the histological data, a correlation analysis was performed between peak plasma cystatin C (48 h) and peak plasma osteopontin (72 h) concentrations and tubular necrosis score. Peak plasma cystatin C concentrations showed only a marginal correlation (Figure 5A), while peak plasma osteopontin levels were strongly and significantly correlated with the extent of tubular necrosis and dilatation (Figure 5B). Based on the




Figure 2

Plasma activity of DPP4 (A), plasma concentration of active GLP-1 24 h (B) and 168 h post IRI (C). Values shown are means ± SEM. **P* < 0.05, significantly different as indicated; Kruskal–Wallis test or one-way ANOVA.




Figure 3

Renal DPP4 activity. Mean area AUC was calculated for each treatment group-specific δ OD 405 nm·s⁻¹ curve, and resulting mean values were analysed. Values shown are means ± SEM. **P* < 0.05, significantly different as indicated; one-way ANOVA.

observation of a strong positive correlation between plasma osteopontin concentrations and the extent of tubular damage, together with a trend towards a reduction of plasma osteopontin by DPP4 inhibition, renal expression of osteopontin was analysed by Western blot (Figure 6A, B). Compared with the sham group, renal osteopontin expression was significantly increased in the placebo group. DPP4 inhibition prevented any increases in renal osteopontin levels, leading to significantly reduced osteopontin levels compared with the placebo group in all DPP4 inhibitor treatment groups (Figure 6A, B). Contrary to plasma osteopontin, renal osteopontin levels were not correlated to the extent of tubular damage (data not shown).

Plasma and renal cytokine levels

Analysis of cytokine levels in plasma collected at study end showed no significant alterations among all groups (Table 2). However, the renal expression of several cytokines was differently regulated. IRI lead to a significant up-regulation of CCL2, IL-1 β , IL-5 and KC in placebo-treated animals compared with sham animals. Linagliptin, vildagliptin and sitagliptin treatment did not result in any significant differences compared with the placebo group. However, prolonged/dose-adjusted sitagliptin-treated animals showed significantly higher concentrations of IL-6 compared with the placebo group (Table 2).

Discussion

In the current study, the effects of the DPP4 inhibitors linagliptin, vildagliptin and sitagliptin on renal IRI were analysed. DPP4 inhibition induced a reduced plasma DPP4 activity in all treatment groups, paralleled by an increase of active GLP-1 concentrations, 24 h after IRI. Renal DPP4




Figure 4

Tubular dilatation and tubular necrosis score. (A) Representative microphotographs from kidney sections of each treatment group. (B) Tubular dilatation score. (C) Tubular necrosis score. Values shown are means \pm SEM. * $P < 0.05$, significantly different as indicated; one-way ANOVA.

activity measured at study end was significantly inhibited in the linagliptin group, but only numerically reduced in the prolonged/dose-adjusted sitagliptin group. Plasma cystatin C concentrations peaked 48 h after IRI and were higher in the placebo group compared with the sham group. Plasma osteopontin concentrations showed a peak at 72 h, with higher plasma levels in the placebo compared with the sham group. DPP4 inhibitor treatment did not affect plasma cystatin C concentrations at any point but showed a trend towards a reduction of plasma osteopontin levels. Histological evaluation of the kidney samples revealed tubular necrosis and tubular dilatation in all groups subjected to IRI.

DPP4 inhibition by prolonged/dose-adjusted sitagliptin treatment (and partly by regular sitagliptin treatment) reduced both tubular necrosis and dilatation. Peak plasma cystatin C concentrations at 48 h were weakly correlated, and peak plasma osteopontin concentrations at 72 h were strongly correlated with the extent of tubular necrosis and dilatation. Analysis of renal osteopontin expression revealed a significant reduction in all DPP4 inhibitor groups, compared with placebo. Measurement of renal cytokine expression demonstrated an IRI-related up-regulation of CCL2, IL-1 β , IL-5 and KC. Furthermore, a significant up-regulation of renal IL-6 expression, which was absent in the placebo group, was




Figure 5

Correlation between plasma cystatin C/osteopontin and tubular necrosis score.

observed in prolonged/dose-adjusted sitagliptin treated animals. Taken together, DPP4 inhibition did not affect the impairment of glomerular function due to IRI, measured by assessing plasma cystatin C concentrations, but did provide beneficial effects, in terms of tubular damage. One limitation of the current study, similar to the majority of previous studies (Vaghasiya *et al.*, 2011; Glorie *et al.*, 2012; Nuransoy *et al.*, 2015; Youssef *et al.*, 2015), is that no urinary parameters were investigated, which could have improved assessments of the effects of DPP4 inhibition in renal IRI on glomerular function.

To the best of our knowledge, there are six published studies and one conference abstract that investigated DPP4 inhibition in renal IRI (Vaghasiya *et al.*, 2011; Daniel *et al.*, 2012; Glorie *et al.*, 2012; Chen *et al.*, 2013; Chang *et al.*, 2015; Nuransoy *et al.*, 2015; Youssef *et al.*, 2015). Details of these studies are summarized in Table 3. Albeit employing a different assessment, quantitative and qualitative scoring systems, six of these studies were able to demonstrate a beneficial effect of DPP4 inhibition in renal IRI on tubular damage (Vaghasiya *et al.*, 2011; Glorie *et al.*, 2012; Chen *et al.*, 2013; Chang *et al.*, 2015; Nuransoy *et al.*, 2015; Youssef *et al.*, 2015). Results of the current study substantiate these previous findings. In regard to beneficial effects of DPP4 inhibition on glomerular function, two studies, both investigating sitagliptin in renal IRI, also did not demonstrate any significant results (Chang *et al.*, 2015; Nuransoy *et al.*, 2015). Four other studies did observe significant effects of

DPP4 inhibition on glomerular function (Vaghasiya *et al.*, 2011; Glorie *et al.*, 2012; Chen *et al.*, 2013; Youssef *et al.*, 2015). However, both conflicting and supporting data have to be interpreted carefully, as the designs of all the available studies are very heterogeneous (Table 3). In a study of Vaghasiya *et al.* (2011), the authors did show protective effects of DPP4 inhibition on glomerular function, but only in a diabetic rat model of renal IRI. Glorie *et al.* (2012), using a non-diabetic rat model (left renal pedicle clamping for 30 min followed by right nephrectomy), induced mild renal impairment with peak glomerular dysfunction 12 h after IRI. The authors demonstrated a significant reduction of serum creatinine at 12 h and to a minor extent at 48 h after IRI. Contrary to all other available studies that used oral drug administration, vildagliptin was administered intravenously 15 min prior to IRI (Glorie *et al.*, 2012). Chen *et al.* (2013) did observe positive effects of DPP4 inhibition on parameters of glomerular function, yet excessive suprathreshold doses of sitagliptin ($600 \text{ mg}\cdot\text{kg}^{-1}\cdot\text{day}^{-1}$) were used, which might elicit a positive effect on renal function in this animal model, but could possibly pose a risk and would be hard to translate to humans (Bloomfield *et al.*, 2009). Setting results of the current study into context with results from comparable studies (Glorie *et al.*, 2012; Youssef *et al.*, 2015), it has to be taken into account that in the current study, different to all previous studies, IRI was induced 2 weeks after uninephrectomy, in a state of mild renal impairment (Arsenijevic




Figure 6

Renal expression of osteopontin. (A) Representative Western blot bands showing the expression of osteopontin (OPN, upper band; around 65 kDa) and the expression of actin (lower band; around 40 kDa). (B) Protein expression of renal osteopontin (random units). Values shown are means \pm SEM. * $P < 0.05$, significantly different as indicated; one-way ANOVA.

et al., 2015). It has been shown that this additional insult results in a more pronounced post-ischaemic functional impairment, which could have masked minor positive effects of DPP4 inhibition (Vercauteren *et al.*, 1999). However, inducing renal IRI on top of mild renal impairment might represent the clinical situation better, as impaired renal function is a strong risk factor for acute renal failure, and the prevalence for acute renal failure in healthy individuals is low (Hsu *et al.*, 2008). Furthermore, the different DPP4 inhibitor dosing, treatment timing and pharmacokinetic profiles must also be considered as other factors influencing the study results (Table 3). Vildagliptin, for example, has a considerably lower IC_{50} towards DPP-8 and DPP-9 than other DPP4 inhibitors, as has linagliptin towards fibroblast activating protein (Thomas *et al.*, 2008; Huan *et al.*, 2015). Depending on the drug doses used, together with putative disease-related expression changes, different outcomes in animal studies might be observed. Furthermore, there are differences in the pharmacokinetics of DPP4 inhibitors. In the current study, renal DPP4 activity was measured at study end 168 h after induction of IRI. Although linagliptin treatment was discontinued on the day of IRI induction, renal DPP4 activity was still significantly inhibited 1 week later. This reduction of renal DPP4 activity was not accompanied by increased plasma active GLP-1 levels, suggesting a minor role of renal DPP4 in inactivating circulating GLP-1 levels. Contrary to data from the linagliptin group, no significant inhibition could be observed in the vildagliptin and sitagliptin group. The prolonged and dose-

adjusted sitagliptin group only showed a trend towards reduced renal DPP4 activity, but displayed significantly increased active GLP-1 plasma levels. A possible explanation of the different renal DPP4 inhibition can be based on pharmacokinetic properties. Linagliptin exhibits a 10–15 times greater apparent volume of distribution, with a higher tissue-to-blood ratio and more than 1000-fold lower k_{off} rate from the DPP4 protein compared with sitagliptin (Filippatos *et al.*, 2014; Huan *et al.*, 2015; Nakamaru *et al.*, 2016; Schnapp *et al.*, 2016). Regardless of renal DPP4 activity, the strongest effects on tubular damage were observed in the prolonged/dose-adjusted sitagliptin group. In this group, contrary to all other treatment groups, active GLP-1 levels were increased until the end of the study, which, in context with previous findings, could be one underlying mechanism (Chang *et al.*, 2015). In summary, different models of IRI, different study durations and different drug dosing, employing structurally different DPP4 inhibitors, could have been influential factors underlying the different results in AKI settings with regards to DPP4 inhibition, IRI and glomerular function. Another important reason for the observed heterogeneity in study results might be that current clinical definitions of AKI are focused on changes of glomerular function, by measuring suitable surrogate parameters, such as creatinine or cystatin C (Kellum, 2015). These definitions ignore the actual morphological consequences of renal IRI, which is an impairment of tubular function due to tubular alterations such as tubular necrosis and tubular dilatation (Racusen and Solez, 1986; Endre *et al.*, 2013). In the current study, IRI had a modest effect on increasing plasma cystatin C, although tubular damage was very pronounced. Furthermore, correlation analysis displayed only a weak positive association between plasma cystatin C and tubular necrosis but a very strong positive correlation between plasma osteopontin, a marker of tubular damage and tubular necrosis (Xie *et al.*, 2001; Zhang *et al.*, 2010). A previous study showed that DPP4 inhibition leads to a reduction of plasma osteopontin levels (Chaykovska *et al.*, 2011). Also in the current study, DPP4 inhibition lowered plasma osteopontin levels, but this effect did not reach statistical significance. However, the most pronounced effect in this regard was observed for the prolonged/dose-adjusted sitagliptin treatment, which also was associated with the strongest amelioration of histomorphological tubular damage and the only group with significantly elevated active GLP-1 plasma levels until study end. This might indicate an advantage of a prolonged treatment regimen. Analysis of renal osteopontin expression showed that osteopontin was significantly up-regulated in the placebo group and uniformly down-regulated to levels of the sham group in all DPP4 inhibitor groups. To the best of our knowledge, this is the first observation of a down-regulating effect elicited by DPP4 inhibition on renal osteopontin expression. Osteopontin, a secreted 44 kDa glycoprotein, is up-regulated in injured kidney cells and is involved in immune and anti-apoptotic processes next to a variety of other functions (Xie *et al.*, 2001). Previous studies have demonstrated that osteopontin expression is increased in renal IRI and that its modulation can alter the course of disease (Padanilam *et al.*, 1996; Wagner *et al.*, 2003; Zhang *et al.*, 2010). However, results are conflicting, attributing to osteopontin both a positive and a

Table 2
Plasma and renal cytokine levels

	Sham	Placebo	Linagliptin	Vildagliptin	Sitagliptin	Prolonged/dose-adjusted sitagliptin
Plasma						
CCl2 pg·mL ⁻¹	2864.7 ± 684.6 [8]	4477.9 ± 2262.9 [12]	3293.2 ± 2675.1 [13]	3420.1 ± 1277.0 [13]	2841.0 ± 944.0 [14]	2829.9 ± 832.6 [13]
IFN-γ pg·mL ⁻¹	0.8 ± 0.6 [8]	1.1 ± 0.8 [13]	1.4 ± 0.8 [14]	1.0 ± 0.6 [13]	1.2 ± 0.6 [14]	1.4 ± 0.7 [13]
IL-10 pg·mL ⁻¹	5.3 ± 2.1 [8]	8.8 ± 5.4 [13]	8.4 ± 3.7 [14]	8.4 ± 3.1 [13]	7.1 ± 2.9 [14]	10 ± 4.1 [13]
IL-13 pg·mL ⁻¹	1.3 ± 0.5 [8]	1.4 ± 0.6 [13]	1.6 ± 0.7 [14]	1.2 ± 0.6 [13]	1.4 ± 0.5 [14]	1.7 ± 0.8 [13]
IL-1β plasma pg·mL ⁻¹	3.1 ± 2.3 [7]	3.4 ± 2.2 [9]	3.7 ± 2.5 [12]	3.0 ± 2.8 [10]	5.6 ± 4.6 [11]	4.8 ± 3.9 [12]
IL-4 pg·mL ⁻¹	0.3 ± 0.1 [8]	0.4 ± 0.3 [13]	0.5 ± 0.2 [14]	0.4 ± 0.2 [13]	0.4 ± 0.1 [14]	0.5 ± 0.2 [13]
IL-5 pg·mL ⁻¹	5.2 ± 3.7 [5]	4.3 ± 4.0 [11]	8.9 ± 4.7 [13]	6.1 ± 5.0 [11]	4.1 ± 3.4 [14]	5.9 ± 4.6 [11]
IL-6 pg·mL ⁻¹	14.3 ± 11.5 [8]	17.0 ± 16.9 [13]	27.4 ± 16.5 [13]	18.3 ± 18.3 [13]	17.5 ± 11.1 [14]	23.4 ± 16.4 [13]
KC pg·mL ⁻¹	53.3 ± 22.1 [8]	75.1 ± 47.5 [13]	50.4 ± 37.6 [14]	54.9 ± 29.1 [13]	38.6 ± 8.5 [14]	49.9 ± 16.2 [13]
TNF-α pg·mL ⁻¹	2.6 ± 0.7 [7]	2.6 ± 1.1 [14]	2.1 ± 0.7 [14]	2.1 ± 0.7 [13]	2.6 ± 0.9 [14]	3.0 ± 0.8 [13]
Kidney						
CCl2 pg·mL ⁻¹	59.1 ± 24.7 [8]*	192.2 ± 98.5 [14]	247.6 ± 164.6 [14]	221.2 ± 172.9 [14]	165.7 ± 75.7 [14]	266.0 ± 187.4 [14]
IFN-γ pg·mL ⁻¹	4.0 ± 1.2 [8]	3.0 ± 1.0 [14]	3.0 ± 1.0 [14]	2.9 ± 1.3 [14]	3.1 ± 0.9 [14]	3.6 ± 1.4 [14]
IL-10 pg·mL ⁻¹	1.4 ± 0.5 [6]	2.9 ± 2.3 [14]	3.1 ± 2.0 [14]	3.4 ± 1.7 [14]	3.8 ± 3.6 [14]	3.5 ± 2.0 [14]
IL-13 pg·mL ⁻¹	2.4 ± 1.7 [8]	2.6 ± 0.6 [14]	2.7 ± 0.6 [14]	3.1 ± 0.9 [14]	2.8 ± 0.8 [14]	3.2 ± 0.9 [14]
IL-1β plasma pg·mL ⁻¹	44.2 ± 8.7 [8]*	76.4 ± 19.7 [14]	81.7 ± 17.6 [14]	74.5 ± 24.1 [14]	60.4 ± 16.8 [14]	66.6 ± 20.7 [14]
IL-4 pg·mL ⁻¹	0.4 ± 0.3 [8]	0.5 ± 0.2 [14]	0.5 ± 0.1 [14]	0.5 ± 0.1 [14]	0.5 ± 0.3 [14]	0.6 ± 0.2 [14]
IL-5 pg·mL ⁻¹	17.3 ± 5.6 [8]*	34.0 ± 14.3 [14]	35.1 ± 10.6 [14]	36.6 ± 16.2 [14]	30.3 ± 8.7 [14]	37.1 ± 14.4 [14]
IL-6 pg·mL ⁻¹	139.7 ± 40.9 [8]	149.7 ± 41.9 [14]	150.8 ± 33.1 [14]	181.6 ± 65.0 [14]	172.9 ± 44.0 [14]	200.2 ± 57.5 [14]*
KC pg·mL ⁻¹	12.3 ± 2.9 [8]*	48.6 ± 41.9 [14]	45.8 ± 15.6 [14]	49.5 ± 29.9 [14]	31.1 ± 23.3 [14]	44.5 ± 40.6 [14]
TNF-α pg·mL ⁻¹	8.5 ± 1.5 [8]	11.9 ± 2.9 [14]	11.3 ± 2.2 [14]	11.9 ± 4.4 [14]	9.4 ± 2.5 [14]	11.0 ± 3.5 [14]

Values displayed are means ± SD.

*P < 0.05, significantly different from placebo; Kruskal–Wallis test or one-way ANOVA.

Table 3
Studies investigating DPP4 inhibition in models of renal IRI

Study	Design	IRI	Outcome	Overall
Sitagliptin Nuransoy <i>et al.</i> (2015)	Healthy, female rats, 14 days, 5 mg·kg ⁻¹ ·day ⁻¹ pre IRI	60 min IRI + UniNX	↓ Oxidative stress ↑ Antioxidative enzymes ↓ Tubular damage ↔ Serum creatinine 24 h post IRI	Tubular effects
Sitagliptin Vaghasiya <i>et al.</i> (2011)	Diabetic, male/female rats, 14 days, 5 mg·kg ⁻¹ ·day ⁻¹ pre IRI	30 min bilateral IRI	↓ Serum AST, creatinine, urea nitrogen 24 h post IRI ↑ Antioxidative enzymes ↓ Tubular damage	Tubular and glomerular effects
Sitagliptin Youssef <i>et al.</i> (2015)	Healthy, male rats, 5 mg·kg ⁻¹ 5/22 h post IRI	30 min bilateral IRI	↓ Serum urea, creatinine, cystatin C 24 h post IRI ↓ Tubular damage 24 h	Tubular and glomerular effects
Sitagliptin Chang <i>et al.</i> (2015)	Healthy, male rats, 3 days, 300/600 mg·kg ⁻¹ ·day ⁻¹ post IRI	60 min bilateral IRI	↑ GLP-1 and GLP-1R ↓ Tubular damage 72 h post IRI Numerical reduction of serum creatinine 72 h post IRI	Tubular effects
Sitagliptin Chen <i>et al.</i> (2013)	Healthy, male rats, 3 days, 600 mg·kg ⁻¹ ·day ⁻¹ post IRI	60 min bilateral IRI	↓ Serum creatinine 24 h and 72 h post IRI ↓ Tubular damage 24 and 72 h post IRI ↓ Inflammation/apoptosis/oxidative stress	Tubular and glomerular effects
Vildagliptin Glorie <i>et al.</i> , 2012	Healthy, male rats, 1/10 mg·kg ⁻¹ i.v. 15 pre IRI	30 min IRI + UniNX	↓ Serum creatinine 12 and 48 h post IRI ↓ Tubular necrosis 12 h post IRI, ↔ at 48 h post IRI ↓ Inflammation/apoptosis/oxidative stress	Tubular and glomerular effects
DPP4 ^{-/-} rats Daniel <i>et al.</i> (2012) (Abstract)	DPP4 ^{-/-} rats	45 min IRI + UniNX	↑ Serum creatinine 24 h post IRI versus wildtype ↑ Tubular damage versus wildtype ↑ Macrophage infiltration versus wildtype	Detrimental tubular and glomerular effects

negative impact on renal IRI (Padanilam *et al.*, 1996; Nambi *et al.*, 1997; Noiri *et al.*, 1999; Persy *et al.*, 1999, 2003; Zhang *et al.*, 2010). Interpretation of results on osteopontin from the current study indicate a mild positive impact of reduced osteopontin levels in renal IRI, but leave room for speculation. Other differently designed studies with kidney assessment at various earlier time points are needed to properly investigate the seemingly complex relationship between DPP4 inhibition, renal and plasma osteopontin levels and renal damage. Given the role of osteopontin in inflammation, cytokine levels in plasma (obtained at study end) and cytokine levels in kidney homogenates were measured. No significant changes in plasma cytokine levels could be observed, which might be due to the long interval between IRI and cytokine measurements (168 h post IRI). Cytokine levels in renal homogenates of placebo-treated animals displayed a significant up-regulation of CCL2, IL-1 β , IL-5 and KC levels. DPP4 inhibitor treatment did not significantly affect these IRI-related changes in renal cytokine expression. The prolonged/dose-adjusted sitagliptin group displayed a weak but significant up-regulation of renal IL-6 expression. As an up-regulation of IL-6 was absent from the placebo group, the observed increase of IL-6 in the prolonged/dose-adjusted sitagliptin group, which displayed significantly elevated active GLP-1 plasma levels, might have been due to an GIP-mediated effect on IL-6 expression (Ellingsgaard *et al.*, 2011; Timper *et al.*, 2013; Kahles *et al.*, 2014; Timper *et al.*, 2016).

Taking into account that the design of the available studies of DPP4 inhibition in renal IRI is very heterogenous (Table 3), results of the current study are in agreement with previous studies, especially regarding beneficial effects of DPP4 inhibition on IRI-mediated tubular damage. Although only some studies employed a quantitative assessment of histopathological kidney changes, all of the previously mentioned studies observed positive effects of DPP4 inhibition on histological readouts of kidney injury (Vaghasiya *et al.*, 2011; Glorie *et al.*, 2012; Chen *et al.*, 2013; Chang *et al.*, 2015; Nuransoy *et al.*, 2015; Youssef *et al.*, 2015). One strength of the current study is the head-to-head comparison of several structurally unrelated DPP4 inhibitors, also in a clinical relevant regimen of dose adjustment. Taken together, our data suggest DPP4 inhibition is safe in models of IRI and might elicit beneficial effects. In this respect, a continuous treatment with DPP4 inhibitors or having patients on such drugs, when expecting an increased risk for AKI (e.g. during cardiac and transplantation surgeries) could be of benefit. Detrimental effects of DPP4 deficiency, which were observed in DPP4-deficient rats subjected to IRI (Daniel *et al.*, 2012), were not observed by any other study including the current one. This might be related to differences of a pharmacological inhibition of DPP4 in comparison with a full genetic knockout, probably due to missing crucial protein/protein interaction of DPP4 (Mulvihill and Drucker, 2014). Results of the current study support earlier evidence that DPP4 inhibition exerts beneficial effects in renal tubules in models of IRI. Regarding favourable effects of DPP4 inhibition on glomerular function, more homogenously designed studies, measuring the same parameters of glomerular function, are needed.

In conclusion, this study adds substantial evidence to previous findings, showing that DPP4 inhibition in IRI is safe and might exert beneficial effects on the renal tubules. Clinical

evaluation of the current findings is still missing, but results of this and previous studies in regard to drug safety could be of clinical importance. Current evidence implies that no drug discontinuation would be needed in clinical situations with an elevated risk for renal IRI, such as cardiac surgery. However, due to the impairment of renal function, dose adjustment would be necessary (Scheen, 2015). From a practical point of view, this would favour linagliptin in a clinical setting, as it is the only DPP4 inhibitor, which does not need to be dose-adjusted in renal impairment (Scheen, 2015).

Acknowledgements

B.H. received a research grant from Boehringer Ingelheim Pharma for this project.

Author contributions

B.H., C.R. and K.v.W. designed the experiment. C.R., K.v.W. and O.T. performed the animal experiment. A.M.S., L.G.F., V.A., C.C., S.E.D.P. and A.A.H. performed the molecular biological and histological analyses and statistical evaluation of the acquired data. C.R. analysed the final data set and wrote the initial manuscript. T.K. performed analysis of renal and plasma DPP4 activity and contributed to the discussion. J.R. analysed cytokine levels in plasma and renal homogenates. All authors contributed to revising and editing of the manuscript and gave their approval to publishing the final manuscript.

Conflict of interest

T.K. and J.R. are research employees of Boehringer Ingelheim Pharma. The other authors declare no conflicts interest.

Declaration of transparency and scientific rigour

This Declaration acknowledges that this paper adheres to the principles for transparent reporting and scientific rigour of preclinical research recommended by funding agencies, publishers and other organisations engaged with supporting research.

References

- Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE *et al.* (2015). The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. *Br J Pharmacol* 172: 6024–6109.
- Arsenijevic D, Cajot J-F, Dulloo AG, Montani J-P (2015). Uninephrectomy in rats on a fixed food intake results in adipose tissue lipolysis implicating spleen cytokines. *Front Physiol* 6: 195.
- Baetta R, Corsini A (2011). Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. *Drugs* 71: 1441–1467.

- Basile DP, Anderson MD, Sutton TA (2012). Pathophysiology of acute kidney injury. *Compr Physiol* 2: 1303–1353.
- Belayev LY, Palevsky PM (2014). The link between acute kidney injury and chronic kidney disease. *Curr Opin Nephrol Hypertens* 23: 149–154.
- Bloomfield DM, Krishna R, Hreniuk D, Hickey L, Ghosh K, Bergman AJ *et al.* (2009). A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects. *J Clin Pharmacol* 49: 937–946.
- Blydt-Hansen TD, Katori M, Lassman C, Ke B, Coito AJ, Iyer S *et al.* (2003). Gene transfer-induced local heme oxygenase-1 overexpression protects rat kidney transplants from ischemia/reperfusion injury. *J Am Soc Nephrol* 14: 745–754.
- Bonventre JV, Yang L (2011). Cellular pathophysiology of ischemic acute kidney injury. *J Clin Invest* 121: 4210–4221.
- Ceriello A, Sportiello L, Rafaniello C, Rossi F (2014). DPP-4 inhibitors: pharmacological differences and their clinical implications. *Expert Opin Drug Saf* 13 (Suppl 1): S57–S68.
- Chang M, Chen C, Chen Y, Wu Y, Zhen Y, Leu S *et al.* (2015). Sitagliptin protects rat kidneys from acute ischemia-reperfusion injury via upregulation of GLP-1 and GLP-1 receptors. *Acta Pharmacol Sin* 36: 119–130.
- Chawla LS, Amdur RL, Amodeo S, Kimmel PL, Palant CE (2011). The severity of acute kidney injury predicts progression to chronic kidney disease. *Kidney Int* 79: 1361–1369.
- Chaykovska L, von Websky K, Rahnenführer J, Alter M, Heiden S, Fuchs H *et al.* (2011). Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy. *PLoS One* 6: e27861.
- Chen Y-T, Tsai T-H, Yang C-C, Sun C-K, Chang L-T, Chen H-H *et al.* (2013). Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction. *J Transl Med* 11: 270.
- Coca SG, Singanamala S, Parikh CR (2012). Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. *Kidney Int* 81: 442–448.
- Connelly KA, Bowskill BB, Advani SL, Thai K, Chen L-H, Kabir MG *et al.* (2014). Dipeptidyl peptidase-4 inhibition improves left ventricular function in chronic kidney disease. *Clin Invest Med* 37: E172.
- Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SPA, Giembycz MA *et al.* (2015). Experimental design and analysis and their reporting: new guidance for publication in *BJP*. *Br J Pharmacol* 172: 3461–3471.
- Daniel C, Grigo C, Wang Z, von Hörsten S, Amann K (2012). CD26/DPP4 deficiency impairs kidney function in the ischemia/reperfusion model in the rat. Poster (P351) presented at: 4. Jahrestagung der Deutschen Gesellschaft für Nephrologie. 08.10.2012. Hamburg, Germany. Available at: <http://www.aey-congresse.com/nephrokongress2012/Sitzung.aspx?PSID=1921&PAID=4866>
- Ellingsgaard H, Hauselmann I, Schuler B, Habib AM, Baggio LL, Meier DT *et al.* (2011). Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. *Nat Med* 17: 1481–1489.
- Endre ZH, Kellum JA, Di Somma S, Doi K, Goldstein SL, Koyner JL *et al.* (2013). Differential diagnosis of AKI in clinical practice by functional and damage biomarkers: workgroup statements from the tenth Acute Dialysis Quality Initiative Consensus Conference. *Contrib Nephrol* 182: 30–44.
- Field A (2013). *Discovering Statistics Using IBM SPSS Statistics*. SAGE: London, UK.
- Filippatos TD, Athyros VG, Elisaf MS (2014). The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]. *Expert Opin Drug Metab Toxicol* 10: 787–812.
- Glorie LFF, Verhulst A, Matheeußen V, Baerts L, Magielse J, Hermans N *et al.* (2012). DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury. *Am J Physiol Renal Physiol* 303: F681–F688.
- Hochoer B, Sharkovska Y, Mark M, Klein T, Pfab T (2013). The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats. *Int J Cardiol* 167: 87–93.
- Hsu CY, Ordoñez JD, Chertow GM, Fan D, McCulloch CE, Go AS (2008). The risk of acute renal failure in patients with chronic kidney disease. *Kidney Int* 74: 101–107.
- Huan Y, Jiang Q, Liu J, Shen Z (2015). Establishment of a dipeptidyl peptidases (DPP) 8/9 expressing cell model for evaluating the selectivity of DPP4 inhibitors. *J Pharmacol Toxicol Methods* 71: 8–12.
- Jungraithmayr W, De Meester I, Matheeußen V, Baerts L, Arni S, Weder W (2012). CD26/DPP-4 inhibition recruits regenerative stem cells via stromal cell-derived factor-1 and beneficially influences ischaemia-reperfusion injury in mouse lung transplantation. *Eur J Cardiothorac Surg* 41: 1166–1173.
- Kahles F, Meyer C, Möllmann J, Diebold S, Findeisen HM, Leberherz C *et al.* (2014). GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering. *Diabetes* 63: 3221–3229.
- Kam Tao Li P, Burdman EA, Mehta RL (2013). Acute kidney injury: global health alert. *J Nephropathol* 2: 90–97.
- Kellum JA (2015). Diagnostic criteria for acute kidney injury: present and future. *Crit Care Clin* 31: 621–632.
- Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. *Br J Pharmacol* 160: 1577–1579.
- Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2012). Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. *Osteoarthritis Cartilage* 20: 256–260.
- Kramann R, Kusaba T, Humphreys BD (2015). Who regenerates the kidney tubule? *Nephrol Dial Transplant* 30: 903–910.
- Lafrance J-P, Miller DR (2010). Acute kidney injury associates with increased long-term mortality. *JASN* 21: 345–352.
- McGrath JC, Lilley E (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in *BJP*. *Br J Pharmacol* 172: 3189–3193.
- Mentlein R (1999). Dipeptidyl-peptidase IV (CD26) – role in the inactivation of regulatory peptides. *Regul Pept* 85: 9–24.
- Mulvihill EE, Drucker DJ (2014). Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. *Endocr Rev* 35: 992–1019.
- Muth JED (2014). *Basic Statistics and Pharmaceutical Statistical Applications*, Third edn. CRC Press: Boca Raton, FL, USA.
- Nakamaru Y, Akahoshi F, Iijima H, Hisanaga N, Kume T (2016). Tissue distribution of teneligliptin in rats and comparisons with data reported for other dipeptidyl peptidase-4 inhibitors. *Biopharm Drug Dispos* 37: 142–155.
- Nambi P, Gellai M, Wu HL, Prabhakar U (1997). Upregulation of osteopontin in ischemia-induced renal failure in rats: a role for ET-1? *Biochem Biophys Res Commun* 241: 212–214.

- Noiri E, Dickman K, Miller F, Romanov G, Romanov VI, Shaw R *et al.* (1999). Reduced tolerance to acute renal ischemia in mice with a targeted disruption of the osteopontin gene. *Kidney Int* 56: 74–82.
- Nuransoy A, Beytur A, Polat A, Samdanci E, Sagir M, Parlakpınar H (2015). Protective effect of sitagliptin against renal ischemia reperfusion injury in rats. *Ren Fail* 37: 687–693.
- Padanilam BJ, Martin DR, Hammerman MR (1996). Insulin-like growth factor I-enhanced renal expression of osteopontin after acute ischemic injury in rats. *Endocrinology* 137: 2133–2140.
- Park Y, Hirose R, Dang K, Xu F, Behrends M, Tan V *et al.* (2008). Increased severity of renal ischemia-reperfusion injury with venous clamping compared to arterial clamping in a rat model. *Surgery* 143: 243–251.
- Persy VP, Verstrepen WA, Ysebaert DK, De Greef KE, De Broe ME (1999). Differences in osteopontin up-regulation between proximal and distal tubules after renal ischemia/reperfusion. *Kidney Int* 56: 601–611.
- Persy VP, Verhulst A, Ysebaert DK, De Greef KE, De Broe ME (2003). Reduced postischemic macrophage infiltration and interstitial fibrosis in osteopontin knockout mice. *Kidney Int* 63: 543–553.
- Putra SED, Tsuprykov O, Von Websky K, Ritter T, Reichetzeder C, Hocher B (2014). Dealing with large sample sizes: comparison of a new one spot dot blot method to western blot. *Clin Lab* 60: 1871–1877.
- Racusen LC, Solez K (1986). Nephrotoxic tubular and interstitial lesions: morphology and classification. *Toxicol Pathol* 14: 45–57.
- Sauvé M, Ban K, Momen MA, Zhou Y-Q, Henkelman RM, Husain M *et al.* (2010). Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. *Diabetes* 59: 1063–1073.
- Scheen AJ (2015). Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. *Clin Pharmacokinet* 54: 1–21.
- Schnapp G, Klein T, Hoevels Y, Bakker RA, Nar H (2016). Comparative analysis of binding kinetics and thermodynamics of dipeptidyl peptidase-4 inhibitors and their relationship to structure. *J Med Chem* 59: 7466–7477.
- Silver SA, Cardinal H, Colwell K, Burger D, Dickhout JG (2015). Acute kidney injury: preclinical innovations, challenges, and opportunities for translation. *Can J Kidney Health Dis* 2: 30.
- Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SPH *et al.* (2016). The IUPHAR/BPS guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. *Nucleic Acids Res* 44: D1054–D1068.
- Thakar CV, Christianson A, Freyberg R, Almenoff P, Render ML (2009). Incidence and outcomes of acute kidney injury in intensive care units: a veteran's administration study. *Crit Care Med* 37: 2552–2558.
- Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M (2008). (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. *J Pharmacol Exp Ther* 325: 175–182.
- Timper K, Grisouard J, Sauter NS, Herzog-Radimerski T, Dembinski K, Peterli R *et al.* (2013). Glucose-dependent insulinotropic polypeptide induces cytokine expression, lipolysis, and insulin resistance in human adipocytes. *Am J Physiol Endocrinol Metab* 304: E1–13.
- Timper K, Dalmas E, Dror E, Rütli S, Thienel C, Sauter NS *et al.* (2016). Glucose-dependent insulinotropic peptide stimulates glucagon-like peptide 1 production by pancreatic islets via interleukin 6, produced by α cells. *Gastroenterology* 151: 165–179.
- Uchida S, Endou H (1988). Substrate specificity to maintain cellular ATP along the mouse nephron. *Am J Physiol* 255: F977–F983.
- Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S *et al.* (2005). Acute renal failure in critically ill patients: a multinational, multicenter study. *JAMA* 294: 813–818.
- Vaghasiya J, Sheth N, Bhalodia Y, Manek R (2011). Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes. *Regul Pept* 166: 48–54.
- Vercauteren SR, Ysebaert DK, De Greef KE, Eyskens EJ, De Broe ME (1999). Chronic reduction in renal mass in the rat attenuates ischemia/reperfusion injury and does not impair tubular regeneration. *J Am Soc Nephrol* 10: 2551–2561.
- Wagner M, Cadetg P, Ruf R, Mazzucchelli L, Ferrari P, Redaelli CA (2003). Heme oxygenase-1 attenuates ischemia/reperfusion-induced apoptosis and improves survival in rat renal allografts. *Kidney Int* 63: 1564–1573.
- Xie Y, Sakatsume M, Nishi S, Narita I, Arakawa M, Gejyo F (2001). Expression, roles, receptors, and regulation of osteopontin in the kidney. *Kidney Int* 60: 1645–1657.
- Youssef MI, Mahmoud AAA, Abdelghany RH (2015). A new combination of sitagliptin and furosemide protects against remote myocardial injury induced by renal ischemia/reperfusion in rats. *Biochem Pharmacol* 96: 20–29.
- Zhang Z-X, Shek K, Wang S, Huang X, Lau A, Yin Z *et al.* (2010). Osteopontin expressed in tubular epithelial cells regulates NK cell-mediated kidney ischemia reperfusion injury. *J Immunol* 185: 967–973.

bph.13822.pdf

by Sulistyo Reichetzedder

Submission date: 01-Feb-2021 02:07PM (UTC+0700)

Submission ID: 1498884899

File name: bph.13822.pdf (1.4M)

Word count: 9684

Character count: 51292

RESEARCH PAPER

Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury

Correspondence Professor Berthold Hocher, ¹¹Institute of Nutritional Science, University of Potsdam, Arthur-Scheunert-Allee 114-116, 14558 Nuthetal, Potsdam, Germany E-mail: hocher@uni-potsdam.de

Received 25 July 2016; ⁸⁹Revised 2 April 2017; Accepted 5 April 2017

Christoph Reichetzeder^{1,2}, Karoline von Websky^{1,2}, Oleg Tsuprykov^{1,2,9}, Azadeh Mohagheghi Samarini^{1,3}, Luise Gabriele Falke², Sulistyono Emantoko Dwi Putra^{1,6}, Ahmed Abdallah Hasan^{1,7}, Viktoriia Antonenko^{1,2}, Caterina Curato^{4,5}, Jörg Rippmann⁸, Thomas Klein⁸ and Berthold Hocher^{1,9,10}

¹Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany, ²Center for Cardiovascular Research, Charité – Universitätsmedizin Berlin, Berlin, Germany, ³Institute of Aquaculture, University of South Bohemia, České Budějovice, Czech Republic, ⁴German Rheumatism Research Center (DRFZ), Berlin, Germany, ⁵Cluster of Excellence NeuroCure, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁶Faculty of Biotechnology, University of Surabaya, Surabaya, Indonesia, ⁷Department of Biochemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt, ⁸Cardio Metabolic Diseases, Boehringer-Ingelheim Pharma GmbH&Co KG, Biberach, Germany, ⁹Institut für Laboratoriumsmedizin, Berlin, Germany, and ¹⁰Department of Basic Medicine, Medical College of Hunan Normal University, Changsha, China

BACKGROUND AND PURPOSE

Results regarding protective effects of dipeptidyl peptidase 4 (DPP4) inhibitors in renal ischaemia–reperfusion injury (IRI) are conflicting. Here we have compared structurally unrelated DPP4 inhibitors in a model of renal IRI.

EXPERIMENTAL APPROACH

IRI was induced in uninephrectomized male rats by renal artery clamping for 30 min. The sham group was uninephrectomized but not subjected to IRI. DPP4 inhibitors/vehicle were given p.o. once daily on three consecutive days prior to IRI: linagliptin (1.5 mg·kg⁻¹·day⁻¹), vildagliptin (8 mg·kg⁻¹·day⁻¹) and sitagliptin (30 mg·kg⁻¹·day⁻¹). An additional group received sitagliptin until study end (before IRI: 30 mg·kg⁻¹·day⁻¹; after IRI: 15 mg·kg⁻¹·day⁻¹).

KEY RESULTS

Plasma-active glucagon-like peptide type 1 (GLP-1) increased threefold to fourfold in all DPP4 inhibitor groups 24 h after IRI. Plasma cystatin C, a marker of GFR, peaked 48 h after IRI. Compared with the placebo group, DPP4 inhibition did not reduce increased plasma cystatin C levels. DPP4 inhibitors ameliorated histopathologically assessed tubular damage with varying degrees of drug-specific efficacies. Renal osteopontin expression was uniformly reduced by all DPP4 inhibitors. IRI-related increased renal cytokine expression was not decreased by DPP4 inhibition. Renal DPP4 activity at study end was significantly inhibited in the linagliptin group, but only numerically reduced in the prolonged/dose-adjusted sitagliptin group. Active GLP-1 plasma levels at study end were increased only in the prolonged/dose-adjusted sitagliptin treatment group.

CONCLUSIONS AND IMPLICATIONS

In rats with renal IRI, DPP4 inhibition did not alter plasma cystatin C, a marker of glomerular function, but may protect against tubular damage.

Abbreviations

AKI, acute kidney injury; CKD, chronic kidney disease; DPP4, dipeptidyl peptidase 4; ESRD, end-stage renal disease; GLP-1, gastric inhibitory polypeptide; GLP-1, glucagon-like peptide type 1; IRI, ischaemia reperfusion injury; KC, keratinocyte chemoattractant; MCP-1, monocyte chemoattractant protein 1; UniNX, uni-nephrectomy

Introduction

Acute kidney injury (AKI) is a frequent and increasingly prevalent syndrome, defined by a rapid deterioration of kidney function (Kam Tao Li *et al.*, 2013; Kramann *et al.*, 2015), which is associated with high morbidity and mortality (Lafrance and Miller, 2010; Kam Tao Li *et al.*, 2013). The incidence of AKI is increasing and expected to double over the next 10 years (Silver *et al.*, 2015). Data from recent observational studies suggest an association between AKI and chronic kidney disease (CKD) and end-stage renal disease (ESRD) (Coca *et al.*, 2012). About 14% of patients with AKI progress to stage 4 CKD, and more severe cases of AKI are associated with a higher risk for progression to CKD (Chawla *et al.*, 2011; Coca *et al.*, 2012). The high incidence of AKI is discussed as one possible explanation for the increasing burden of CKD and ESRD (Coca *et al.*, 2012; Belayev and Palevsky, 2014). There are many risk factors and causes for AKI (Hsu *et al.*, 2008; Basile *et al.*, 2012). Among these, the most prominent aetiology of AKI is acute tubular necrosis as a consequence of an ischaemic or nephrotoxic insult (Basile *et al.*, 2012; Kramann *et al.*, 2015). In a clinical setting, kidney hypoxia or ischaemia-reperfusion injury (IRI) inevitably occurs during surgery involving renal or aortic vascular occlusion. Of all cases of hospital-acquired AKI, approximately 30–40% occur during surgery, making the perioperative period one of the leading causes of AKI (Uchino *et al.*, 2005; Thakare *et al.*, 2009). The most vulnerable renal tissue with regards to both ischaemic and toxic insults are tubular epithelial cells (Konventre and Yang, 2011; Kramann *et al.*, 2015). These cells rely on aerobic respiration and have a high metabolic demand due to their involvement in fluid and electrolyte reabsorption, making them uniquely susceptible to IRI (Uchida and Endou, 1988; Kramann *et al.*, 2015).

Dipeptidyl peptidase 4 (DPP4) inhibitors are a new drug class approved for the treatment of type 2 diabetes. Its anti-diabetic effects are elicited by an inhibition of the ubiquitously expressed serine protease DPP4, which mediates the degradation of incretins such as glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) (Mentlein, 1999). Moreover, DPP4 also has several other substrates, including growth factors, neuro- and vasoactive peptides and chemokines (Mentlein, 1999). Based on the structure, DPP4 inhibitors can be broadly divided into peptidomimetics (e.g. vildagliptin) and non-peptidomimetics (e.g. linagliptin, sitagliptin) (Baetta and Corsini, 2011; Ceriello *et al.*, 2014). Although their chemical structures are different, all DPP4 inhibitors are substrate competitive active site binders but show different binding characteristics on the DPP4 protein (Schnapp *et al.*, 2016).

Preclinical evidence suggests that DPP4 inhibitors have protective effects on the heart and lungs (Sauvé *et al.*, 2010; Jungraithmayr *et al.*, 2012; Hocher *et al.*, 2013). As DPP4 is strongly expressed in the kidney (Mentlein, 1999), DPP4 inhibition might also elicit protective effects in renal IRI. Several studies already investigated putative protective effects in renal IRI, but with conflicting results. Therefore, we studied the effects of three structurally different DPP4 inhibitors - linagliptin, vildagliptin and sitagliptin - on the

outcome of IR-induced AKI in uni-nephrectomized rats. One additional arm (sitagliptin) was treated throughout the entire experiment and dose adjusted.

Methods

Animals

All animal care and experimental procedures were approved by the Committee on the Ethics of Animal Experiments (Landesamt fuer Gesundheit und Soziales), Berlin, Germany. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny *et al.*, 2010; Kilkenny *et al.*, 2012; McGrath & Lilley, 2015). Male Wistar rats (10 sham animals, 14 placebo-treated animals and 14 per treatment group), aged 5–6 weeks, weighing 200–250 g, were obtained from Charles River, Germany, and housed in groups under standardized specific pathogen-free conditions (12 h light/dark cycle, 23°C, humidity of 50–60%, rat type IV cages) with food and water *ad libitum*. After an acclimatization period of 1 week, all animals were subjected to uni-nephrectomy. Two weeks later, the remaining kidney was exposed to IRI by clamping the renal artery for 30 min, and sham surgery was performed without clamping. Animals were randomly allocated to six different groups: sham, placebo, linagliptin (1.5 mg·kg⁻¹·day⁻¹), vildagliptin (8 mg·kg⁻¹·day⁻¹), sitagliptin (30 mg·kg⁻¹·day⁻¹) and prolonged/dose-adjusted sitagliptin, a group which was treated with sitagliptin until the end of study in order to block the DPP4 activity during the entire experiment. In this group, treatment started with 30 mg·kg⁻¹ once daily on two consecutive days prior to IRI; after that, the dose was adjusted to 15 mg·kg⁻¹·day⁻¹ because of renal failure. All groups received DPP4 inhibitor treatment or vehicle *via* gavage once daily on two consecutive days prior to IRI and on the day of surgery 2 h before IRI. Doses in the current study were selected based on previous DPP4 inhibitor studies in similar settings and calculated on AUC (Chaykovska *et al.*, 2011; Connelly *et al.*, 2014).

Baseline blood samples were taken from the tail vein. Blood samples were collected at baseline 24 h before and 24, 48, 72 h and 1 week (168 h) after IRI. Afterwards, animals were killed under deep isoflurane anaesthesia and organs were harvested. Two sham animals were excluded from the study because of critical weight loss occurring shortly after the surgical sham intervention (probably due to infection), reducing the *n*-value of the sham group to eight. The *n*-value variation of measured plasma parameters among the analysed experimental groups originated from either limited plasma sample volume or from plasma samples that gave a NaN (not a number) result in the respective assay. The *n*-value variation of histological readouts among the experimental groups occurred because of suboptimal tissue processing in one batch of samples due to technical difficulties of the automated tissue processor. The whole animal experiment was performed in a randomized fashion using six arms. Rats were randomly allocated to six different arms, with each arm containing about the same number of animals from every treatment group. The animal study was performed by different investigators than the following experiments, ensuring that all analyses were performed in a blinded fashion.

Biomarkers of renal function and injury

Plasma **cystatin C**, a biomarker of glomerular filtration rate and **osteopontin**, a biomarker of tubular damage, were measured by automated immunoassays (Myriad RBM, Inc., Austin, Texas, USA).

DPP4 activity and GLP-1 measurements

Whole blood was collected into lithium heparin-treated tubes and plasma was separated by centrifugation. Activity of plasma DPP4 was assessed using a previously reported method (Chaykovska *et al.*, 2011). A 20 μL volume of plasma was diluted with 30 μL of DPP4 assay buffer (100 $\text{mmol}\cdot\text{L}^{-1}$ Tris, 100 $\text{mmol}\cdot\text{L}^{-1}$ NaCl, adjusted to pH 7.8 with HCl) and mixed with 50 μL substrate (final concentration 100 mM H-Ala-Pro-7-amido-4-trifluoromethylcoumarin). After incubation at room temperature for 10 min, fluorescence of the wells was determined using a Wallac Victor 1420 Multilabel Counter at an excitation wavelength of 405 nm and an emission wavelength of 535 nm. Active (uncleaved, 7–36 amide or 7–37) GLP-1 was detected in plasma samples using a commercially available multiarray assay system (K150JWC from Meso Scale Discovery, Rockwell, Maryland, USA) following the instructions provided by the supplier. This antibody only detects active GLP-1 (9–36 amide or 7–37 GLP-1) but not cleaved and inactive GLP-1 (9–36 amide or 9–37 GLP-1).

Cytokine detection from plasma and kidney homogenates

For preparation of kidney extracts, 50 mg of tissue was lysed in 500 μL of Meso Scale Discovery (Gaithersburg, MD, USA) lysis buffer (MSD R60TX-2) with protease inhibitor cocktails from Thermo Fisher, Germany (1861278), and Sigma, Germany (P5726), using FastPrep device (MP Biomedicals) at 4°C, 30 s, 6000 \times g. Homogenates were centrifuged for 10 min, 4°C at 10 000 \times g. Supernatants were adjusted to protein concentration of 20 $\text{mg}\cdot\text{mL}^{-1}$ and used for cytokine analysis and DPP4 activity measurements.

Cytokine concentrations of kidney tissue (50 μL of lysate) and plasma samples (undiluted samples) were analysed by Meso Scale Discovery (Gaithersburg, MD, USA) immunoassays according to the manufacturer's protocols using a MSD Custom Rat Cytokine kit (K153A0H-2). Concentrations of CCL2 were analysed in 25 μL aliquots by the Rat Mcp-1 Ultra Sensitive Kit (K153AYC-2). Absolute concentrations were calculated by comparison with a series of standard dilutions of the respective cytokine measured on the same plate. In both plasma and renal homogenates, concentrations of CCL2, IFN- γ , IL-10, IL-13, IL-1 β , IL-4, IL-5, IL-6, keratinocyte chemoattractant (KC) and TNF- α were analysed.

Renal DPP4 activity

For DPP4 activity, 2 μL of kidney homogenate extracts were diluted with 130 μL of HEPES buffer (10 mM) pH 7.6 and incubated for 10 min at 37°C in 96-well plates. A total of 100 μL of Gly-Pro-pNA (4-nitroaniline, Sigma Aldrich, Germany) was added as DPP4 substrate (1 mM solution) and kinetics (20 min, every 60 s) were detected at 405 nm. The reaction was observed to be linear up until 11 min; thus, this timeframe was used to assess renal DPP4 activity.

Because Gly-Pro-pNA is an artificial DPP4 substrate and high protease activity is present in the kidney, we added 10 μM sitagliptin to a parallel set of extracts, to define DPP4-specific activity baseline. Values were given as specific DPP4 activity in (δ OD405 $\text{nm}\cdot\text{min}^{-1}$) by subtracting sitagliptin-inhibited baseline. For graphic display and statistical analysis, treatment group-specific AUC of the linear kinetic period (0–11 min) were calculated (minutes were converted to seconds).

Histological assessment of kidney tubular necrosis and tubular dilatation

For histological evaluation, all samples were embedded in paraffin, cut in 3 μm sections and stained with haematoxylin–eosin. Tubular dilatation and tubular necrosis were analysed using a semiquantitative grading score on haematoxylin–eosin stained kidney samples by two blinded independent investigators. At least 25 viewing fields of the outer medulla were randomly chosen with 200 \times magnification per each kidney sample. Tubular dilatation was assessed by a three-point scoring system, where 1 indicates <25% tubules show dilatation and thinned epithelium, 2 indicates 25 to 50% tubules show dilatation and thinned epithelium, and 3 indicates >50% tubules show dilatation and thinned epithelium (Blydt-Hansen *et al.*, 2003). Tubular necrosis was classified according to a 1–5 score as follows: grade 1 (no to mild damage) = less than 10% tubular necrosis, grade 2 (mild to moderate damage) = 10 to 25% tubular cell necrosis, grade 3 (moderate to severe damage) = 25 to 50% tubular cell necrosis, grade 4 (severe damage) = 50 to 75% and grade 5 (severe to very severe) = greater than 75% tubular cell necrosis (Park *et al.*, 2008).

Western blot analysis of renal protein expression

Western blots were performed as previously described (Putra *et al.*, 2014). Briefly, renal samples containing both cortex and medulla were crushed in a metal mortar after cooling liquid nitrogen. Protein was extracted using a urea/thiourea buffer [2 M thiourea, 7 M urea, 2% SDS, 1% DTT] and protease inhibitor (Complete Mini, Cat. no.: 11 697 498 001, Roche). Protein extracts were separated by SDS-PAGE employing a 10% polyacrylamide gel. Following SDS-PAGE gels were blotted to nitrocellulose membrane (AmershamTM HybondTM ECL, GE Healthcare) using a Biorad Trans-Blot semidry blotter and transfer buffer (184 mM glycine, 24 mM Tris, 20% methanol). The anti-osteopontin antibody (sc-21742, Santa Cruz Biotechnology) was used at a dilution of 1:1000 and the anti-housekeeping protein actin antibody (A5060, Sigma-Aldrich) at a dilution of 1:10 000. The signals were developed using enhanced chemiluminescence. The developed membranes were digitalized using a 600 dpi scanner resolution and analysed with AlphaEaseFCTM.

Statistical analysis

The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis *et al.*, 2015). Statistical analyses were performed using SPSS Version 20 and Graph Pad Prism 6.

Quantitative data in text and tables are expressed as means \pm SD. In the figures, data are presented as means \pm SEM. Data were analysed for normal distribution using the Kolmogorov–Smirnov test. Not normally distributed data were analysed using the Kruskal–Wallis test followed by a Dunn *post hoc* test. For normally distributed data, group comparisons were performed employing one-way ANOVA. Heterogeneity of variance was assessed using Levene's test. If results of the test were significant ($P < 0.05$), Welch's F was used. According to heterogeneity of variances, either a Bonferroni (equal variances assumed) or a Games–Howell (unequal variances assumed) *post hoc* was used, as recommended (Field, 2013; Muth, 2014). *Post hoc* tests were only run if F achieved $P < 0.05$. For the comparison of parameters measured over time, two-way ANOVA was used followed by a Bonferroni *post hoc* test. To analyse if two parameters are correlated, Pearson bivariate correlation analysis was employed. P values lower than 0.05 were considered statistically significant.

Materials

Linagliptin [BI1356; 8-[(3R)-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4-methyl-quinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione] was developed and synthesized by Boehringer Ingelheim Pharma GmbH and Co. KG (Biberach an der Riss, Germany), and vildagliptin [(2S)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile] and sitagliptin [(3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-ol] were from Sequoia, Oxford, UK. The compounds were dissolved in 0.5% Natrosol, and were administered p.o.

Nomenclature of targets and ligands

Key protein targets and ligands in this article are hyperlinked to corresponding entries in <http://www.guidetopharmacology.org>, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan *et al.*, 2016), and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander *et al.*, 2015).

Table 1

Basic animal characteristics and summary of kidney parameters

	Sham (8)	Placebo (14)	Linagliptin (14)	Vildagliptin (14)	Sitagliptin (14)	Prolonged/dose-adjusted sitagliptin (14)
Baseline weight (g)	335.1 \pm 10.7	333.1 \pm 32.8	327.3 \pm 24.1	327.1 \pm 30.8	337.1 \pm 21.6	321.3 \pm 27.3
Final weight (g)	362.4 \pm 15.9	345.3 \pm 26.4	344.9 \pm 21.9	343.7 \pm 28.0	351.6 \pm 21.6	334.0 \pm 28.8
Kidney weight (g)	1.7 \pm 0.2*	2.5 \pm 0.7	2.3 \pm 0.2	2.5 \pm 0.5	2.4 \pm 0.5	2.2 \pm 0.3
Rel. kidney weight (g g ⁻¹ BW \times 100)	0.46 \pm 0.04*	0.72 \pm 0.17	0.66 \pm 0.10	0.74 \pm 0.12	0.68 \pm 0.12	0.66 \pm 0.12
Tubular dilatation score	1.1 \pm 0.16*	2.8 \pm 0.17	2.4 \pm 0.41	2.8 \pm 0.26	2.3 \pm 0.46*	2.0 \pm 0.52*
Tubular necrosis score	1.2 \pm 0.15*	4.5 \pm 0.48	4.0 \pm 0.78	4.5 \pm 0.62	3.6 \pm 0.94	3.0 \pm 1.03*
Renal osteopontin expression	0.75 \pm 0.41*	1.17 \pm 0.43	0.68 \pm 0.22*	0.70 \pm 0.34*	0.76 \pm 0.34*	0.67 \pm 0.29*

* $P < 0.05$, significantly different from placebo; one-way ANOVA. Values displayed are means \pm SD.

Results

Basic characteristics of the treatment groups are displayed in Table 1. There were no statistical significant differences regarding baseline and final body weight.

Kidney function

The impact of IRI on kidney function was assessed by plasma cystatin C and osteopontin levels. IRI induced steadily increasing plasma cystatin C concentrations, which peaked 48 h after clamping. The placebo group displayed significantly higher cystatin C levels 48 h after IRI compared with the sham group (Figure 1A). Treatment with DPP4 inhibitors did not significantly affect plasma cystatin C concentrations compared with placebo at any point (Figure 1A). Furthermore, IRI induced an increase in plasma osteopontin levels, which peaked 72 h after clamping (Figure 1B). Compared with the sham group, the placebo group displayed significantly elevated plasma osteopontin levels at 24 h, 48 h and 72 h after clamping (Figure 1B). Treatment with DPP4 inhibitors resulted in numerically lower plasma osteopontin concentrations compared with the placebo group, but these differences did not reach statistical significance at any point (Figure 1B).

DPP4 activity and active GLP-1 levels in plasma

All groups with DPP4 inhibitor treatment displayed a significantly reduced DPP4 activity 24 h after induction of IRI compared with the placebo group (Figure 2A). Plasma concentrations of active GLP-1 were significantly increased in all DPP4 inhibitor treatment groups versus the placebo group, up to 24 h after IRI (Figure 2B). At the end of the study, 168 h after IRI, active GLP-1 plasma concentrations of all treatment groups except the prolonged/dose-adjusted sitagliptin group returned to baseline. The prolonged/dose-adjusted sitagliptin group, as expected, still displayed significantly elevated active GLP-1 plasma levels (Figure 2C).




Figure 1

Concentrations of plasma cystatin C and osteopontin over the course of the study. (A) Plasma cystatin C concentrations; *n*-values: sham (0 h: *n* = 8; 24 h: *n* = 8; 48 h: *n* = 8; 72 h: *n* = 8; 168 h: *n* = 8), placebo (0 h: *n* = 12; 24 h: *n* = 14; 48 h: *n* = 14; 72 h: *n* = 14; 168 h: *n* = 14), linagliptin (0 h: *n* = 14; 24 h: *n* = 14; 48 h: *n* = 14; 72 h: *n* = 13; 168 h: *n* = 14), vildagliptin (0 h: *n* = 14; 24 h: *n* = 14; 48 h: *n* = 14; 72 h: *n* = 14; 168 h: *n* = 14), sitagliptin (0 h: *n* = 14; 24 h: *n* = 14; 48 h: *n* = 14; 72 h: *n* = 14; 168 h: *n* = 13), prolonged/dose-adjusted sitagliptin (0 h: *n* = 14; 24 h: *n* = 14; 48 h: *n* = 14; 72 h: *n* = 14; 168 h: *n* = 14). Values shown are means \pm SEM. **P* < 0.05, significantly different as indicated; two-way ANOVA. (B) Plasma osteopontin concentrations; *n*-values: sham (0 h: *n* = 8; 24 h: *n* = 8; 48 h: *n* = 8; 72 h: *n* = 8; 168 h: *n* = 8), placebo (0 h: *n* = 12; 24 h: *n* = 14; 48 h: *n* = 14; 72 h: *n* = 14; 168 h: *n* = 14), linagliptin (0 h: *n* = 14; 24 h: *n* = 14; 48 h: *n* = 14; 72 h: *n* = 13; 168 h: *n* = 14), vildagliptin (0 h: *n* = 14; 24 h: *n* = 14; 48 h: *n* = 14; 72 h: *n* = 14; 168 h: *n* = 14), sitagliptin (0 h: *n* = 14; 24 h: *n* = 14; 48 h: *n* = 14; 72 h: *n* = 14; 168 h: *n* = 13), prolonged/dose-adjusted sitagliptin (0 h: *n* = 14; 24 h: *n* = 14; 48 h: *n* = 14; 72 h: *n* = 14; 168 h: *n* = 14). Values shown are means \pm SEM. **P* < 0.05, significantly different as indicated; two-way ANOVA.

Renal DPP4 activity

The AUC of renal DPP4 activity, assessed 168 h after IRI, was not significantly different between the sham and placebo group. Kidney homogenates of linagliptin-treated animals still displayed a significantly reduced DPP4 activity compared with placebo-treated animals. Also renal DPP4 activity of prolonged/dose-adjusted sitagliptin-treated animals was numerically reduced, but did not reach statistical significance. Vildagliptin- and sitagliptin-treated animals displayed no reduction of renal DPP4 activity (Figure 3).

Kidney morphology

Kidney weight, both absolute and in relation to body weight, was significantly increased in the placebo group compared with the sham group (Table 1). IRI caused a significant increase of the tubular necrosis and tubular dilatation score

in the placebo group compared with the sham group (Table 1; Figure 4B). The prolonged/dose-adjusted treatment with sitagliptin led to a significant decrease of both tubular necrosis and dilatation. Regular sitagliptin treatment significantly reduced tubular dilatation, but only numerically affected tubular necrosis score. Also linagliptin treatment resulted in a non-significant, numerically decreased tubular necrosis and dilatation score, whereas vildagliptin treatment was without effect (Table 1; Figure 4C).

Furthermore, to assess the validity of the histological data, a correlation analysis was performed between peak plasma cystatin C (48 h) and peak plasma osteopontin (72 h) concentrations and tubular necrosis score. Peak plasma cystatin C concentrations showed only a marginal correlation (Figure 5A), while peak plasma osteopontin levels were strongly and significantly correlated with the extent of tubular necrosis and dilatation (Figure 5B). Based on the




Figure 2

Plasma activity of DPP4 (A), plasma concentration of active GLP-1 24 h (B) and 168 h post IRI (C). Values shown are means \pm SEM. * $P < 0.05$, significantly different as indicated; Kruskal–Wallis test or one-way ANOVA.




Figure 3

Renal DPP4 activity. Mean area AUC was calculated for each treatment group-specific Δ OD 405 nm·s⁻¹ curve, and resulting mean values were analysed. Values shown are means \pm SEM. * $P < 0.05$, significantly different as indicated; one-way ANOVA.

observation of a strong positive correlation between plasma osteopontin concentrations and the extent of tubular damage, together with a trend towards a reduction of plasma osteopontin by DPP4 inhibition, renal expression of osteopontin was analysed by Western blot (Figure 6A, B). Compared with the sham group, renal osteopontin expression was significantly increased in the placebo group. DPP4 inhibition prevented any increases in renal osteopontin levels, leading to significantly reduced osteopontin levels compared with the placebo group in all DPP4 inhibitor treatment groups (Figure 6A, B). Contrary to plasma osteopontin, renal osteopontin levels were not correlated to the extent of tubular damage (data not shown).

Plasma and renal cytokine levels

Analysis of cytokine levels in plasma collected at study end showed no significant alterations among all groups (Table 2). However, the renal expression of several cytokines was differently regulated. IRI lead to a significant up-regulation of CCL2, IL-1 β , IL-5 and KC in placebo-treated animals compared with sham animals. Linagliptin, vildagliptin and sitagliptin treatment did not result in any significant differences compared with the placebo group. However, prolonged/dose-adjusted sitagliptin-treated animals showed significantly higher concentrations of IL-6 compared with the placebo group (Table 2).

Discussion

In the current study, the ²⁹ effects of the DPP4 inhibitors linagliptin, vildagliptin and sitagliptin on renal IRI were analysed. DPP4 inhibition induced a reduced plasma DPP4 activity in all treatment groups, paralleled by an increase of active GLP-1 concentrations, 24 h after IRI. Renal DPP4




Figure 4

Tubular dilatation and tubular necrosis score. (A) Representative microphotographs from kidney sections of each treatment group. (B) Tubular dilatation score. (C) Tubular necrosis score. Values shown are means \pm SEM. * $P < 0.05$, significantly different as indicated; one-way ANOVA.

activity measured at study end was significantly inhibited in the linagliptin group, but only numerically reduced in the prolonged/dose-adjusted sitagliptin group. Plasma cystatin C concentrations peaked 48 h after IRI and were higher in the placebo group compared with the sham group. Plasma osteopontin concentrations showed a peak at 72 h, with higher plasma levels in the placebo compared with the sham group. DPP4 inhibitor treatment did not affect plasma cystatin C concentrations at any point but showed a trend towards a reduction of plasma osteopontin levels. Histological evaluation of the kidney samples revealed tubular necrosis and tubular dilatation in all groups subjected to IRI.

DPP4 inhibition by prolonged/dose-adjusted sitagliptin treatment (and partly by regular sitagliptin treatment) reduced both tubular necrosis and dilatation. Peak plasma cystatin C concentrations at 48 h were weakly correlated, and peak plasma osteopontin concentrations at 72 h were strongly correlated with the extent of tubular necrosis and dilatation. Analysis of renal osteopontin expression revealed a significant reduction in all DPP4 inhibitor groups, compared with placebo. Measurement of renal cytokine expression demonstrated an IRI-related up-regulation of CCL2, IL-1 β , IL-5 and KC. Furthermore, a significant up-regulation of renal IL-6 expression, which was absent in the placebo group, was




Figure 5

Correlation between plasma cystatin C/osteopontin and tubular necrosis score.

observed in prolonged/dose-adjusted sitagliptin treated animals. Taken together, DPP4 inhibition did not affect the impairment of glomerular function due to IRI, measured by assessing plasma cystatin C concentrations, but did provide beneficial effects, in terms of tubular damage. One limitation of the current study, similar to the majority of previous studies (Vaghasiya *et al.*, 2011; Glorie *et al.*, 2012; Nuransoy *et al.*, 2015; Youssef *et al.*, 2015), is that no urinary parameters were investigated, which could have improved assessments of the effect of DPP4 inhibition in renal IRI on glomerular function.

To the best of our knowledge, there are six published studies and one conference abstract that investigated DPP4 inhibition in renal IRI (Vaghasiya *et al.*, 2011; Daniel *et al.*, 2012; Glorie *et al.*, 2012; Chen *et al.*, 2013; Chang *et al.*, 2015; Nuransoy *et al.*, 2015; Youssef *et al.*, 2015). Details of these studies are summarized in Table 3. Albeit employing a different assessment, quantitative and qualitative scoring systems, six of these studies were able to demonstrate a beneficial effect of DPP4 inhibition in renal IRI on tubular damage (Vaghasiya *et al.*, 2011; Glorie *et al.*, 2012; Chen *et al.*, 2013; Chang *et al.*, 2015; Nuransoy *et al.*, 2015; Youssef *et al.*, 2015). Results of the current study substantiate these previous findings. In regard to beneficial effects of DPP4 inhibition on glomerular function, two studies, both investigating sitagliptin in renal IRI, also did not demonstrate any significant results (Chang *et al.*, 2015; Nuransoy *et al.*, 2015). Four other studies did observe significant effects of

DPP4 inhibition on glomerular function (Vaghasiya *et al.*, 2011; Glorie *et al.*, 2012; Chen *et al.*, 2013; Youssef *et al.*, 2015). However, both conflicting and supporting data have to be interpreted carefully, as the designs of all the available studies are very heterogeneous (Table 3). In a study of Vaghasiya *et al.* (2011), the authors did show protective effects of DPP4 inhibition on glomerular function, but only in a diabetic rat model of renal IRI. Glorie *et al.* (2012), using a non-diabetic rat model (left renal pedicle clamping for 30 min followed by right nephrectomy), induced mild renal impairment with peak glomerular dysfunction 12 h after IRI. The authors demonstrated a significant reduction of serum creatinine at 12 h and to a minor extent at 48 h after IRI. Contrary to all other available studies that used oral drug administration, vildagliptin was administered intravenously 15 min prior to IRI (Glorie *et al.*, 2012). Chen *et al.* (2013) did observe positive effects of DPP4 inhibition on parameters of glomerular function, yet excessive supratherapeutic doses of sitagliptin (600 mg·kg⁻¹·day⁻¹) were used, which might elicit a positive effect on renal function in this animal model, but could possibly pose a risk and would be hard to translate to humans (Bloomfield *et al.*, 2009). Setting results of the current study into context with results from comparable studies (Glorie *et al.*, 2012; Youssef *et al.*, 2015), it has to be taken into account that in the current study, different to all previous studies, IRI was induced 2 weeks after uninephrectomy, in a state of mild renal impairment (Arsenijevic




Figure 6

Renal expression of osteopontin. (A) Representative Western blot bands showing the expression of osteopontin (OPN, upper band; around 65 kDa) and the expression of actin (lower band; around 40 kDa). (B) Protein expression of renal osteopontin (random units). Values shown are means \pm SEM. * $P < 0.05$, significantly different as indicated; one-way ANOVA.

et al., 2015). It has been shown that this additional insult results in a more pronounced post-ischæmic functional impairment, which could have masked minor positive effects of DPP4 inhibition (Vercauteren *et al.*, 1999). However, inducing renal IRI on top of mild renal impairment might represent the clinical situation because **impaired renal function is a strong risk factor for acute renal failure**, and the prevalence **for acute renal failure** in healthy individuals is low (Hsu *et al.*, 2008). Furthermore, the different DPP4 inhibitor dosing, treatment timing and pharmacokinetic profiles must also be considered as other factors influencing the study results (Table 3). Vildagliptin, for example, has a considerably lower IC_{50} towards DPP-8 and DPP-9 than other DPP4 inhibitors, as has linagliptin towards fibroblast activating protein (Thomas *et al.*, 2008; Huan *et al.*, 2015). Depending on the drug doses used, together with putative disease-related expression changes, different outcomes in animal studies might be observed. Furthermore, there are differences in the pharmacokinetics of DPP4 inhibitors. In the current study, renal DPP4 activity was measured at study end 168 h after induction of IRI. Although linagliptin treatment was discontinued on the day of IRI induction, renal DPP4 activity was still significantly inhibited 1 week later. This reduction of renal DPP4 activity was not accompanied by increased plasma active GLP-1 levels, suggesting a minor role of renal DPP4 in inactivating circulating GLP-1 levels. Contrary to data from the linagliptin group, no significant inhibition could be observed in the vildagliptin and sitagliptin group. The prolonged and dose-

adjusted sitagliptin group only showed a trend towards reduced renal DPP4 activity, but displayed significantly increased active GLP-1 plasma levels. A possible explanation of the different renal DPP4 inhibition can be based on pharmacokinetic properties. Linagliptin exhibits a 10–15 times greater apparent volume of distribution, with a higher tissue-to-blood ratio and more than 1000-fold lower k_{off} rate in the DPP4 protein compared with sitagliptin (Filippatos *et al.*, 2014; Huan *et al.*, 2015; Nakamaru *et al.*, 2016; Schnapp *et al.*, 2016). Regardless of renal DPP4 activity, the strongest effects on tubular damage were observed in the prolonged/dose-adjusted sitagliptin group. In this group, contrary to all other treatment groups, **active GLP-1 levels** were increased until **the end of the study**, which, in context with previous findings, could be one underlying mechanism (Chang *et al.*, 2015). In summary, different models of IRI, different study durations and different drug dosing, employing structurally different DPP4 inhibitors, could have been influential factors underlying the different results in AKI settings with regards to DPP4 inhibition, IRI and glomerular function. Another important reason for the observed heterogeneity in study results might be that current clinical definitions of AKI are focused on changes of glomerular function, by measuring suitable surrogate parameters, such as creatinine or cystatin C (Kellum, 2015). These definitions **ignore the actual morphological consequences of renal IRI, which is an impairment of tubular function due to tubular alterations such as tubular necrosis and tubular dilatation** (Racusen and Solez, 1986; Endre *et al.*, 2013). In the current study, IRI had a modest effect on increasing plasma cystatin C, although tubular damage was very pronounced. Furthermore, correlation analysis displayed only a weak positive association between plasma cystatin C and tubular necrosis but a very strong positive correlation between plasma osteopontin, a marker of tubular damage and tubular necrosis (Xie *et al.*, 2001; Zhang *et al.*, 2010). A previous study showed that DPP4 inhibition leads to a reduction of plasma osteopontin levels (Chaykovska *et al.*, 2011). Also in the current study, DPP4 inhibition lowered plasma osteopontin levels, but **this effect did not reach statistical significance**. However, **the most pronounced effect** in this regard was observed for the prolonged/dose-adjusted sitagliptin treatment, which also was associated with the strongest amelioration of histomorphological tubular damage and the only group with significantly elevated active GLP-1 plasma levels until study end. This might indicate an advantage of a prolonged treatment regimen. Analysis of renal osteopontin expression showed that osteopontin was significantly up-regulated in the **placebo** group and uniformly down-regulated to levels **of the sham group** in all DPP4 inhibitor groups. To **the best of our knowledge**, this is the first observation of a down-regulating effect elicited by DPP4 inhibition on renal osteopontin expression. Osteopontin, a secreted 44 kDa glycoprotein, is up-regulated in injured kidney cells and is involved in immune and anti-apoptotic processes next to a variety of other functions (Xie *et al.*, 2001). Previous studies have demonstrated that osteopontin expression is increased in renal IRI and **its modulation can alter the course of disease** (Padanilam *et al.*, 1996; Wagner *et al.*, 2003; Zhang *et al.*, 2010). However, results are conflicting, attributing to osteopontin both a positive and a

Table 2
Plasma and renal cytokine levels

	Sham	Placebo	Linagliptin	Vildagliptin	Sitagliptin	Prolonged/dose-adjusted sitagliptin
Plasma						
CCL2 pg·mL ⁻¹	2864.7 ± 684.6 [8]	4477.9 ± 2262.9 [12]	3293.2 ± 2675.1 [13]	3420.1 ± 1277.0 [13]	2841.0 ± 944.0 [14]	2829.9 ± 832.6 [13]
IFN-γ pg·mL ⁻¹	0.8 ± 0.6 [8]	1.1 ± 0.8 [13]	1.4 ± 0.8 [14]	1.0 ± 0.6 [13]	1.2 ± 0.6 [14]	1.4 ± 0.7 [13]
IL-10 pg·mL ⁻¹	5.3 ± 2.1 [8]	8.8 ± 5.4 [13]	8.4 ± 3.7 [14]	8.4 ± 3.1 [13]	7.1 ± 2.9 [14]	10 ± 4.1 [13]
IL-13 pg·mL ⁻¹	1.3 ± 0.5 [8]	1.4 ± 0.6 [13]	1.6 ± 0.7 [14]	1.2 ± 0.6 [13]	1.4 ± 0.5 [14]	1.7 ± 0.8 [13]
IL-1β plasma pg·mL ⁻¹	3.1 ± 2.3 [7]	3.4 ± 2.2 [9]	3.7 ± 2.5 [12]	3.0 ± 2.8 [10]	5.6 ± 4.6 [11]	4.8 ± 3.9 [12]
IL-4 pg·mL ⁻¹	0.3 ± 0.1 [8]	0.4 ± 0.3 [13]	0.5 ± 0.2 [14]	0.4 ± 0.2 [13]	0.4 ± 0.1 [14]	0.5 ± 0.2 [13]
IL-5 pg·mL ⁻¹	5.2 ± 3.7 [5]	4.3 ± 4.0 [11]	8.9 ± 4.7 [13]	6.1 ± 5.0 [11]	4.1 ± 3.4 [14]	5.9 ± 4.6 [11]
IL-6 pg·mL ⁻¹	14.3 ± 11.5 [8]	17.0 ± 16.9 [13]	27.4 ± 16.5 [13]	18.3 ± 18.3 [13]	17.5 ± 11.1 [14]	23.4 ± 16.4 [13]
KC pg·mL ⁻¹	53.3 ± 22.1 [8]	75.1 ± 47.5 [13]	50.4 ± 37.6 [14]	54.9 ± 29.1 [13]	38.6 ± 8.5 [14]	49.9 ± 16.2 [13]
TNF-α pg·mL ⁻¹	2.6 ± 0.7 [7]	2.6 ± 1.1 [14]	2.1 ± 0.7 [14]	2.1 ± 0.7 [13]	2.6 ± 0.9 [14]	3.0 ± 0.8 [13]
Kidney						
CCL2 pg·mL ⁻¹	59.1 ± 24.7 [8]*	192.2 ± 98.5 [14]	247.6 ± 164.6 [14]	221.2 ± 172.9 [14]	165.7 ± 75.7 [14]	266.0 ± 187.4 [14]
IFN-γ pg·mL ⁻¹	4.0 ± 1.2 [8]	3.0 ± 1.0 [14]	3.0 ± 1.0 [14]	2.9 ± 1.3 [14]	3.1 ± 0.9 [14]	3.6 ± 1.4 [14]
IL-10 pg·mL ⁻¹	1.4 ± 0.5 [6]	2.9 ± 2.3 [14]	3.1 ± 2.0 [14]	3.4 ± 1.7 [14]	3.8 ± 3.6 [14]	3.5 ± 2.0 [14]
IL-13 pg·mL ⁻¹	2.4 ± 1.7 [8]	2.6 ± 0.6 [14]	2.7 ± 0.6 [14]	3.1 ± 0.9 [14]	2.8 ± 0.8 [14]	3.2 ± 0.9 [14]
IL-1β plasma pg·mL ⁻¹	44.2 ± 8.7 [8]*	76.4 ± 19.7 [14]	81.7 ± 17.6 [14]	74.5 ± 24.1 [14]	60.4 ± 16.8 [14]	66.6 ± 20.7 [14]
IL-4 pg·mL ⁻¹	0.4 ± 0.3 [8]	0.5 ± 0.2 [14]	0.5 ± 0.1 [14]	0.5 ± 0.1 [14]	0.5 ± 0.3 [14]	0.6 ± 0.2 [14]
IL-5 pg·mL ⁻¹	17.3 ± 5.6 [8]*	34.0 ± 14.3 [14]	35.1 ± 10.6 [14]	36.6 ± 16.2 [14]	30.3 ± 8.7 [14]	37.1 ± 14.4 [14]
IL-6 pg·mL ⁻¹	139.7 ± 40.9 [8]	149.7 ± 41.9 [14]	150.8 ± 33.1 [14]	181.6 ± 65.0 [14]	172.9 ± 44.0 [14]	200.2 ± 57.5 [14]*
KC pg·mL ⁻¹	12.3 ± 2.9 [8]*	48.6 ± 41.9 [14]	45.8 ± 15.6 [14]	49.5 ± 29.9 [14]	31.1 ± 23.3 [14]	44.5 ± 40.6 [14]
TNF-α pg·mL ⁻¹	8.5 ± 1.5 [8]	11.9 ± 2.9 [14]	11.3 ± 2.2 [14]	11.9 ± 4.4 [14]	9.4 ± 2.5 [14]	11.0 ± 3.5 [14]

Values displayed are means ± SD.

*P < 0.05, significantly different from placebo; Kruskal–Wallis test or one-way ANOVA.

Table 3
Studies investigating DPP4 inhibition in models of renal IRI

Study	Design	IRI	Outcome	Overall
Sitagliptin Nuransoy <i>et al.</i> (2015) ⁷³	Healthy, female rats, 14 days, 5 mg·kg ⁻¹ ·day ⁻¹ pre IRI	60 min IRI + UniNX	↓ Oxidative stress ↑ Antioxidative enzymes ↓ Tubular damage ↔ Serum creatinine 24 h post IRI	Tubular effects
Sitagliptin Vaghasiya <i>et al.</i> (2011)	Diabetic, male/female rats, 14 days, 5 mg·kg ⁻¹ ·day ⁻¹ pre IRI	30 min bilateral IRI	↓ Serum AST, creatinine, urea nitrogen 24 h post IRI ↑ Antioxidative enzymes ↓ Tubular damage	Tubular and glomerular effects
Sitagliptin Youssef <i>et al.</i> (2015)	Healthy, male rats, 5 mg·kg ⁻¹ 5/22 h post IRI	30 min bilateral IRI	↓ Serum urea, creatinine, cystatin C 24 h post IRI ↓ Tubular damage 24 h	Tubular and glomerular effects
Sitagliptin Chang <i>et al.</i> (2015) ⁵⁷	Healthy, male rats, 3 days, 300/600 mg·kg ⁻¹ ·day ⁻¹ post IRI	60 min bilateral IRI	↑ GLP-1 and GLP-1R ↓ Tubular damage 72 h post IRI Numerical reduction of serum creatinine 72 h post IRI	Tubular effects
Sitagliptin Chen <i>et al.</i> (2013)	Healthy, male rats, 3 days, 600 mg·kg ⁻¹ ·day ⁻¹ post IRI	60 min bilateral IRI	↓ Serum creatinine 24 h and 72 h post IRI ↓ Tubular damage 24 and 72 h post IRI ↓ Inflammation/apoptosis/oxidative stress	Tubular and glomerular effects
Vildagliptin Glorie <i>et al.</i> , 2012	Healthy, male rats, 1/10 mg·kg ⁻¹ i.v. 1.5 pre IRI	30 min IRI + UniNX	↓ Serum creatinine 12 and 48 h post IRI ↓ Tubular necrosis 12 h post IRI, ↔ at 48 h post IRI ⁷² ↓ Inflammation/apoptosis/oxidative stress	Tubular and glomerular effects
DPP4 ^{-/-} rats Daniel <i>et al.</i> (2012) (Abstract)	DPP4 ^{-/-} rats	45 min IRI + UniNX	↑ Serum creatinine 24 h post IRI versus wildtype ↑ Tubular damage versus wildtype ↑ Macrophage infiltration versus wildtype	Detrimental tubular and glomerular effects

39 ative impact on renal IRI (Padanilam *et al.*, 1996; Nambi *et al.*, 1997; Noiri *et al.*, 1999; Persy *et al.*, 1999, 2003; Zhang *et al.*, 2010). Interpretation of results on osteopontin from the current study indicate a mild positive impact of reduced osteopontin levels in renal IRI, but leave room for speculation. Other differently designed studies with kidney assessment at various earlier time points are needed to properly investigate the seemingly complex relationship between DPP4 inhibition, renal and plasma osteopontin levels and renal damage. Given the role of osteopontin in inflammation, cytokine levels in plasma (obtained at study end) and cytokine levels in kidney homogenates were measured. No significant changes in plasma cytokine levels could be observed, which might be due to the long interval between IRI and cytokine measurements (168 h post IRI). Cytokine levels in renal homogenates of placebo-treated animals displayed a significant up-regulation of CCL2, IL-1 β , IL-5 and KC levels. DPP4 inhibitor treatment did not significantly affect these IRI-related changes in renal cytokine expression. The prolonged/dose-adjusted sitagliptin group displayed a weak but significant up-regulation of renal IL-6 expression. As an up-regulation of IL-6 was absent from the placebo group, the observed increase of IL-6 in the prolonged/dose-adjusted sitagliptin group, which displayed significantly elevated active GLP-1 plasma levels, might have been due to an GIP-mediated effect on IL-6 expression (Ellingsgaard *et al.*, 2011; Timper *et al.*, 2013; Kahles *et al.*, 2014; Timper *et al.*, 2016).

Taking into account that the design of the available studies 71 DPP4 inhibition in renal IRI is very heterogenous (Table 3), results of the current study are in agreement with previous studies, especially regarding beneficial effects of DPP4 inhibition on IRI-mediated tubular damage. Although only some studies employed a quantitative assessment of histopathological kidney changes, all of the previously mentioned studies observed positive effects of DPP4 inhibition on histological readouts of kidney injury (Vaghasiya *et al.*, 2011; Glorie *et al.*, 2012; Chen *et al.*, 2013; Chang *et al.*, 2015; Nuransoy *et al.*, 2015; Yusuf *et al.*, 2015). One strength of the current study is the 50 head-to-head comparison of several structurally unrelated DPP4 inhibitors, also in a clinical relevant regimen of dose adjustment. Taken together, our data suggest DPP4 inhibition is safe in models of IRI and might elicit beneficial effects. In this respect, a continuous treatment with DPP4 inhibitors or having patients on such drugs, when expecting an increased risk for AKI (e.g. during cardiac and transplantation surgeries) could be of benefit. Detrimental effects of DPP4 deficiency, which were observed in DPP4-deficient rats subjected to IRI (Daniel *et al.*, 2012), were not observed by any other study including the current one. This might be related to differences of a pharmacological inhibition of DPP4 in comparison with a full genetic knockout, probably due to missing crucial protein/protein interaction of DPP4 (Mulvihill and Drucker, 2014). Results of the current study support earlier evidence that DPP4 inhibition exerts beneficial effects in renal tubules in models of IRI. Regarding favourable effects of DPP4 inhibition on glomerular function, more homogeneously designed studies, measuring the same parameters of glomerular function, are needed.

In conclusion, this study adds substantial evidence to previous findings, showing that DPP4 inhibition in IRI is safe and might exert beneficial effects on the renal tubules. Clinical

evaluation of the current findings is still missing, but results of this and previous studies in regard to drug safety could be of clinical importance. Current evidence implies that no drug discontinuation would be needed in clinical situations with an elevated risk for renal IRI, such as cardiac surgery. However, due to the impairment of renal function, dose adjustment would be necessary (Scheen, 2015). From a practical point of view, this would favour linagliptin in a clinical setting, as it is the only DPP4 inhibitor, which does not need to be dose-adjusted in renal impairment (Scheen, 2015).

Acknowledgements

B.H. received a research grant from Boehringer Ingelheim Pharma for this project.

Author contributions

B.H., C.R. and K.v.W. designed the experiment. C.R., K.v.W. and O.T. performed the animal experiment. A.M.S., L.G.F., V.A., C.C., S.E.D.P. and A.A.H. performed the molecular biological and histological analyses and statistical evaluation of the acquired data. C.R. analysed the final data set and wrote the initial manuscript. T.K. performed analysis of renal and plasma DPP4 activity and contributed to the discussion. J.R. analysed 70 cytokine levels in plasma and renal homogenates. All authors contributed to revising and editing of the manuscript and gave their approval to publishing the final manuscript.

Conflict of interest

T.K. and J.R. are research employees of Boehringer Ingelheim Pharma. The other authors declare no conflicts of interest.

Declaration of transparency and scientific rigour

This Declaration acknowledges that this paper adheres to the principles for transparent reporting and scientific rigour of preclinical research recommended by funding agencies, publishers and other organisations engaged with supporting research.

References

- Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE *et al.* (2015). The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. *Br J Pharmacol* 172: 6024–6109.
- Arsenijevic D, Cajot J-F, Dulloo AG, Montani J-P (2015). Uninephrectomy in rats on a fixed food intake results in adipose tissue lipolysis implicating spleen cytokines. *Front Physiol* 6: 195.
- Baetta R, Corsini A (2011). Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. *Drugs* 71: 1441–1467.

- Basile DP, Anderson MD, Sutton TA (2012). Pathophysiology of acute kidney injury. *Compr Physiol* 2: 1303–1353.
- Belayev LY, Palevsky PM (2014). The link between acute kidney injury and chronic kidney disease. *Curr Opin Nephrol Hypertens* 23: 149–154.
- Bloomfield DM, Krishna R, Hreniuk D, Hickey L, Ghosh K, Bergman AJ *et al.* (2009). A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects. *J Clin Pharmacol* 49: 937–946.
- Blydt-Hansen TD, Katori M, Lassman C, Ke B, Coito AJ, Iyer S *et al.* (2003). Gene transfer-induced local heme oxygenase-1 overexpression protects rat kidney transplants from ischemia/reperfusion injury. *J Am Soc Nephrol* 14: 745–754.
- Bonventre JV, Yang L (2011). Cellular pathophysiology of ischemic acute kidney injury. *J Clin Invest* 121: 4210–4221.
- Ceriello A, Sportiello L, Rafaniello C, Rossi F (2014). DPP-4 inhibitors: pharmacological differences and their clinical implications. *Expert Opin Drug Saf* 13 (Suppl 1): S57–S68.
- Chang M, Chen C, Chen Y, Wu Y, Zhen Y, Leu S *et al.* (2015). Sitagliptin protects rat kidneys from acute ischemia-reperfusion injury via upregulation of GLP-1 and GLP-1 receptors. *Acta Pharmacol Sin* 36: 119–130.
- Chawla LS, Amdur RL, Amodeo S, Kimmel PL, Palant CE (2011). The severity of acute kidney injury predicts progression to chronic kidney disease. *Kidney Int* 79: 1361–1369.
- Chaykovska L, von Websky K, Rahnenführer J, Alter M, Heiden S, Fuchs H *et al.* (2011). Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy. *PLoS One* 6: e27861.
- Chen Y-T, Tsai T-H, Yang C-K, Sun C-K, Chang L-T, Chen H-H *et al.* (2013). Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction. *J Transl Med* 11: 270.
- Coca SG, Singanamala S, Parikh CR (2012). Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. *Kidney Int* 81: 442–448.
- Connelly KA, Bowskill BB, Advani SL, Thai K, Chen L-H, Kabir MG *et al.* (2014). Dipeptidyl peptidase-4 inhibition improves left ventricular function in chronic kidney disease. *Clin Invest Med* 37: E172.
- Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SPA, Giembycz MA *et al.* (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. *Br J Pharmacol* 172: 3461–3471.
- Daniel C, Grigo C, Wang Z, von Hörsten S, Amann K (2012). CD26/DPP4 deficiency impairs kidney function in the ischemia/reperfusion model in the rat. Poster (P351) presented at: 4. Jahrestagung der Deutschen Gesellschaft für Nephrologie. 08.10.2012. Hamburg, Germany. Available at: <http://www.aey-congresse.com/nephro-kongress2012/Sitzung.aspx?PSID=1921&PAID=4866>
- Ellingsgaard H, Hauselmann I, Schuler B, Habib AM, Baggio LL, Meier DT *et al.* (2011). Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. *Nat Med* 17: 1481–1489.
- Endre ZH, Kellum JA, Di Somma S, Doi K, Goldstein SL, Koyner JL *et al.* (2013). Differential diagnosis of AKI in clinical practice by functional and damage biomarkers: workgroup statements from the tenth Acute Dialysis Quality Initiative Consensus Conference. *Contrib Nephrol* 182: 30–44.
- Field A (2013). *Discovering Statistics Using IBM SPSS Statistics*. SAGE: London, UK.
- Filippatos TD, Athyros VG, Elisaf MS (2014). The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]. *Expert Opin Drug Metab Toxicol* 10: 787–812.
- Glorie LLF, Verhulst A, Matheeußen V, Baerts L, Magiels J, Hermans N *et al.* (2012). DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury. *Am J Physiol Renal Physiol* 303: F681–F688.
- Hoher B, Sharkovska Y, Mark M, Klein T, Pfab T (2013). The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats. *Int J Cardiol* 167: 87–93.
- Hsu CY, Ordoñez JD, Chertow GM, Fan D, McCulloch CE, Go AS (2008). The risk of acute renal failure in patients with chronic kidney disease. *Kidney Int* 74: 101–107.
- Huan Y, Jiang Q, Liu J, Shen Z (2015). Establishment of a dipeptidyl peptidases (DPP) 8/9 expressing cell model for evaluating the selectivity of DPP4 inhibitors. *J Pharmacol Toxicol Methods* 71: 8–12.
- Jungraithmayr W, De Meester I, Matheeußen V, Baerts L, Arni S, Weder W (2012). CD26/DPP-4 inhibition recruits regenerative stem cells via stromal cell-derived factor-1 and beneficially influences ischaemia-reperfusion injury in mouse lung transplantation. *Eur J Cardiothorac Surg* 41: 1166–1173.
- Kahles F, Meyer C, Möllmann J, Diebold S, Findeisen HM, Lebherz C *et al.* (2014). GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering. *Diabetes* 63: 3221–3229.
- Kam Tao Li P, Burdmann EA, Mehta RL (2013). Acute kidney injury: global health alert. *J Nephropathol* 2: 90–97.
- Kellum JA (2015). Diagnostic criteria for acute kidney injury: present and future. *Crit Care Clin* 31: 621–632.
- Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. *Br J Pharmacol* 160: 1577–1579.
- Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2012). Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. *Osteoarthritis Cartilage* 20: 256–260.
- Kramann R, Kusaba T, Humphreys BD (2015). Who regenerates the kidney tubule? *Nephrol Dial Transplant* 30: 903–910.
- Lafrance J-P, Miller DR (2010). Acute kidney injury associates with increased long-term mortality. *JASN* 21: 345–352.
- McGrath JC, Lilley E (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. *Br J Pharmacol* 172: 3189–3193.
- Mentlein R (1999). Dipeptidyl-peptidase IV (CD26) – role in the inactivation of regulatory peptides. *Regul Pept* 85: 9–24.
- Mulvihill EE, Drucker DJ (2014). Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. *Endocr Rev* 35: 992–1019.
- Muth JED (2014). *Basic Statistics and Pharmaceutical Statistical Applications*, Third edn. CRC Press: Boca Raton, FL, USA.
- Nakamaru Y, Akahoshi F, Iijima H, Hisanaga N, Kume T (2016). Tissue distribution of teneligliptin in rats and comparisons with data reported for other dipeptidyl peptidase-4 inhibitors. *Biopharm Drug Dispos* 37: 142–155.
- Nambi P, Gellai M, Wu HL, Prabhakar U (1997). Upregulation of osteopontin in ischemia-induced renal failure in rats: a role for ET-1? *Biochem Biophys Res Commun* 241: 212–214.

- Noiri E, Dickman K, Miller F, Romanov G, Romanov VI, Shaw R *et al.* (1999). Reduced tolerance to acute renal ischemia in mice with a targeted disruption of the osteopontin gene. *Kidney Int* 56: 74–82.
- Nuransoy A, Beytur A, Polat A, Samdanci E, Sagir M, Parlakpinar H (2015). Protective effect of sitagliptin against renal ischemia reperfusion injury in rats. *Ren Fail* 37: 687–693.
- Padanilam BJ, Martin DR, Hammerman MR (1996). Insulin-like growth factor I-enhanced renal expression of osteopontin after acute ischemic injury in rats. *Endocrinology* 137: 2133–2140.
- Park Y, Hirose R, Dang K, Xu F, Behrends M, Tan V *et al.* (2008). Increased severity of renal ischemia-reperfusion injury with venous clamping compared to arterial clamping in a rat model. *Surgery* 143: 243–251.
- Persy VP, Verstrepen WA, Ysebaert DK, De Greef KE, De Broe ME (1999). Differences in osteopontin up-regulation between proximal and distal tubules after renal ischemia/reperfusion. *Kidney Int* 56: 601–611.
- Persy VP, Verhulst A, Ysebaert DK, De Greef KE, De Broe ME (2003). Reduced postischemic macrophage infiltration and interstitial fibrosis in osteopontin knockout mice. *Kidney Int* 63: 543–553.
- Putra SED, Tsuprykov O, Von Websky K, Ritter T, Reichetzedder C, Hoher B (2014). Dealing with large sample sizes: comparison of a new one spot dot blot method to western blot. *Clin Lab* 60: 1871–1877.
- Racusen LC, Solez K (1986). Nephrotoxic tubular and interstitial lesions: morphology and classification. *Toxicol Pathol* 14: 45–57.
- Sauvé M, Ban K, Momen MA, Zhou Y-Q, Henkelman RM, Husain M *et al.* (2010). Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. *Diabetes* 59: 1063–1073.
- Scheen AJ (2015). Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. *Clin Pharmacokinet* 54: 1–21.
- Schnapp G, Klein T, Hoevels Y, Bakker RA, Nar H (2016). Comparative analysis of binding kinetics and thermodynamics of dipeptidyl peptidase-4 inhibitors and their relationship to structure. *J Med Chem* 59: 7466–7477.
- Silver SA, Cardinal H, Colwell K, Burger D, Dickhout JG (2015). Acute kidney injury: preclinical innovations, challenges, and opportunities for translation. *Can J Kidney Health Dis* 2: 30.
- Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SPH *et al.* (2016). The IUPHAR/BPS guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. *Nucleic Acids Res* 44: D1054–D1068.
- Thakar CV, Christianson A, Freyberg R, Almenoff P, Render ML (2009). Incidence and outcomes of acute kidney injury in intensive care units: a veteran's administration study. *Crit Care Med* 37: 2552–2558.
- Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M (2008). (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. *J Pharmacol Exp Ther* 325: 175–182.
- Timper K, Grisouard J, Sauter NS, Herzog-Radimerski T, Dembinski K, Peterli R *et al.* (2013). Glucose-dependent insulinotropic polypeptide induces cytokine expression, lipolysis, and insulin resistance in human adipocytes. *Am J Physiol Endocrinol Metab* 304: E1–13.
- Timper K, Dalmas E, Dror E, Rütli S, Thienel C, Sauter NS *et al.* (2016). Glucose-dependent insulinotropic peptide stimulates glucagon-like peptide 1 production by pancreatic islets via interleukin 6, produced by α cells. *Gastroenterology* 151: 165–179.
- Uchida S, Endou H (1988). Substrate specificity to maintain cellular ATP along the mouse nephron. *Am J Physiol* 255: F977–F983.
- Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S *et al.* (2005). Acute renal failure in critically ill patients: a multinational, multicenter study. *JAMA* 294: 813–818.
- Vaghiasiya J, Sheth N, Bhalodia Y, Manek R (2011). Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes. *Regul Pept* 166: 48–54.
- Vercauteren SR, Ysebaert DK, De Greef KE, Eyskens EJ, De Broe ME (1999). Chronic reduction in renal mass in the rat attenuates ischemia/reperfusion injury and does not impair tubular regeneration. *J Am Soc Nephrol* 10: 2551–2561.
- Wagner M, Cadetg P, Ruf R, Mazzucchelli L, Ferrari P, Redaelli CA (2003). Heme oxygenase-1 attenuates ischemia/reperfusion-induced apoptosis and improves survival in rat renal allografts. *Kidney Int* 63: 1564–1573.
- Xie Y, Sakatsume M, Nishi S, Narita I, Arakawa M, Gejyo F (2001). Expression, roles, receptors, and regulation of osteopontin in the kidney. *Kidney Int* 60: 1645–1657.
- Youssef MI, Mahmoud AAA, Abdelghany RH (2015). A new combination of sitagliptin and furosemide protects against remote myocardial injury induced by renal ischemia/reperfusion in rats. *Biochem Pharmacol* 96: 20–29.
- Zhang Z-X, Shek K, Wang S, Huang X, Lau A, Yin Z *et al.* (2010). Osteopontin expressed in tubular epithelial cells regulates NK cell-mediated kidney ischemia reperfusion injury. *J Immunol* 185: 967–973.

ORIGINALITY REPORT

15%

SIMILARITY INDEX

9%

INTERNET SOURCES

12%

PUBLICATIONS

3%

STUDENT PAPERS

PRIMARY SOURCES

1	sajim.co.za Internet Source	<1%
2	www.chemicalregister.com Internet Source	<1%
3	Prioult, G.. "Allergenicity of acidic peptides from bovine @b-lactoglobulin is reduced by hydrolysis with Bifidobacterium lactis NCC362 enzymes", International Dairy Journal, 200505 Publication	<1%
4	Dena E. Rifkin, Steven G. Coca, Kamyar Kalantar-Zadeh. "Does AKI Truly Lead to CKD?", Journal of the American Society of Nephrology, 2012 Publication	<1%
5	repository.ubaya.ac.id Internet Source	<1%
6	Amisha Wallia, Grace Prince, Emilie Touma, Malek El Muayed, Jane Jeffrie Seley. "Caring for Hospitalized Patients with Diabetes Mellitus, Hyperglycemia, and COVID-19: Bridging the	<1%

Remaining Knowledge Gaps", Current Diabetes Reports, 2020

Publication

7	e-lactancia.org Internet Source	<1%
8	nutrition.highwire.org Internet Source	<1%
9	Submitted to Taipei Medical University Student Paper	<1%
10	T. D. Blydt-Hansen. "Gene Transfer-Induced Local Heme Oxygenase-1 Overexpression Protects Rat Kidney Transplants From Ischemia/Reperfusion Injury", Journal of the American Society of Nephrology, 2003 Publication	<1%
11	Submitted to Universita degli Studi di Torino Student Paper	<1%
12	www.iflb.de Internet Source	<1%
13	Fernando Carvalho Oliveira. "Disposição de lodo de esgoto e composto de lixo urbano num latossolo vermelho-amarelo cultivado com cana-de-açúcar", Universidade de Sao Paulo, Agencia USP de Gestao da Informacao Academica (AGUIA), 2000 Publication	<1%

14

ajprenal.physiology.org

Internet Source

<1%

15

ir.canterbury.ac.nz

Internet Source

<1%

16

Submitted to Cardiff University

Student Paper

<1%

17

Tsung-Ming Lee, Wei-Ting Chen, Nen-Chung Chang. "Dipeptidyl Peptidase-4 Inhibition Attenuates Arrhythmias via a Protein Kinase A-Dependent Pathway in Infarcted Hearts", *Circulation Journal*, 2015

Publication

<1%

18

von Haehling, S.. "Inflammation in right ventricular dysfunction due to thromboembolic pulmonary hypertension", *International Journal of Cardiology*, 20101008

Publication

<1%

19

Holger Steinbrenner. "Tumor promoter TPA stimulates MMP-9 secretion from human keratinocytes by activation of superoxide-producing NADPH oxidase", *Free Radical Research*, 3/2005

Publication

<1%

20

www.biosb.com

Internet Source

<1%

Gregory T. Spear, Mario E.A.F. Alves, Mardge

21 H. Cohen, James Bremer, Alan L. Landay. "Relationship of HIV RNA and cytokines in saliva from HIV-infected individuals", FEMS Immunology & Medical Microbiology, 2005
Publication <1%

22 hrcak.srce.hr
Internet Source <1%

23 Submitted to University of South Florida
Student Paper <1%

24 www.thno.org
Internet Source <1%

25 Nephrology, 1991.
Publication <1%

26 Mahesh Basireddy, T. Scott Isbell, Xinjun Teng, Rakesh P. Patel, Anupam Agarwal. "Effects of sodium nitrite on ischemia-reperfusion injury in the rat kidney", American Journal of Physiology-Renal Physiology, 2006
Publication <1%

27 Xiaoyuan Wu, Yuxiang Ma, Xiaoying Lian, Shupeng Lin, Shunlai Shang, Xueyuan Bai. "KLF14 Inhibits Renal Mesangial Cell Proliferation by Promoting Btg2 Gene Expression", Research Square, 2020
Publication <1%

28 Mónica Alonso. "Anti-obesity efficacy of LH-21,

a cannabinoid CB1 receptor antagonist with poor brain penetration, in diet-induced obese rats : LH-21 affects lipogenic proteins in adipose tissue", British Journal of Pharmacology, 04/2012

Publication

<1%

29

"Clinical Diabetes/Therapeutics", Diabetes, 2011

Publication

<1%

30

Submitted to Simmons College

Student Paper

<1%

31

"BASL abstracts", Gut, 5/1/2003

Publication

<1%

32

Enric Esplugues. "Control of TH17 cells occurs in the small intestine", Nature, 07/17/2011

Publication

<1%

33

Roberto Pontarolo, Ana Carolina Gimenez, Thais Martins Guimarães de Francisco, Rômulo Pereira Ribeiro et al. "Simultaneous determination of metformin and vildagliptin in human plasma by a HILIC–MS/MS method", Journal of Chromatography B, 2014

Publication

<1%

34

scholarworks.waldenu.edu

Internet Source

<1%

35

H. J. T. Coelingh Bennink, A.-M. Heegaard, M. Visser, C. F. Holinka, C. Christiansen. "Oral

<1%

bioavailability and bone-sparing effects of
estetrol in an osteoporosis model", Climacteric,
2009

Publication

36

Jiayi He, Lingyi Wu, Zhen Wu, Daodong Pan,
Yuxing Guo, Xiaoqun Zeng, Liwei Lian. " Effect
of on intestinal microflora and immune
parameters: involvement of sex differences ",
Cold Spring Harbor Laboratory, 2018

Publication

37

cjasn.asnjournals.org

Internet Source

<1%

38

Berthold Hocher, Hannah Haumann, Jan
Rahmenführer, Christoph Reichetzer et al.
"Maternal eNOS deficiency determines a fatty
liver phenotype of the offspring in a sex
dependent manner", Epigenetics, 2016

Publication

<1%

39

Mary P Stenzel-Poore. "Neuroprotection by
osteopontin in stroke", Journal of Cerebral Blood
Flow & Metabolism, 02/2005

Publication

<1%

40

ndt.oxfordjournals.org

Internet Source

<1%

41

estudogeral.sib.uc.pt

Internet Source

<1%

42	"WORLD TRANSPLANT CONGRESS 2006 POSTER ABSTRACTS", American Journal of Transplantation, 8/2006 Publication	<1%
43	www.schattauer.de Internet Source	<1%
44	docserv.uni-duesseldorf.de Internet Source	<1%
45	RAG da Silva, AV Karlyshev, NJ Oldfield, KG Wooldridge, CD Bayliss, A Ryan, R Griffin. "Vaccine antigen, Factor H binding protein, is typically a non-lipidated precursor that localises to the meningococcal surface by Slam", Cold Spring Harbor Laboratory, 2019 Publication	<1%
46	bmcgenomics.biomedcentral.com Internet Source	<1%
47	Kramann, R., T. Kusaba, and B. D. Humphreys. "Who regenerates the kidney tubule?", Nephrology Dialysis Transplantation, 2014. Publication	<1%
48	Sandra M Sancho-Martínez, Fernando Sánchez-Juanes, Víctor Blanco-Gozalo, Miguel Fontecha-Barriuso et al. "Urinary TCP1-eta: A Cortical Damage Marker for the Pathophysiological Diagnosis and Prognosis of	<1%

Acute Kidney Injury", Toxicological Sciences, 2019

Publication

-
- | | | |
|----|---|-----|
| 49 | Chia-Ter Chao, Jui Wang, Hon-Yen Wu, Kuo-Liong Chien, Kuan-Yu Hung. "Dipeptidyl peptidase 4 inhibitor use is associated with a lower risk of incident acute kidney injury in patients with diabetes", Oncotarget, 2017
Publication | <1% |
| 50 | pesquisa.bvsalud.org
Internet Source | <1% |
| 51 | M. A. Nauck. "Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective", Acta Diabetologica, 1998
Publication | <1% |
| 52 | ainfo.cnptia.embrapa.br
Internet Source | <1% |
| 53 | care.diabetesjournals.org
Internet Source | <1% |
| 54 | documents.mx
Internet Source | <1% |
| 55 | actavet.vfu.cz
Internet Source | <1% |
| 56 | www.hal.inserm.fr
Internet Source | <1% |

57

real.mtak.hu

Internet Source

<1%

58

www.bentham.org

Internet Source

<1%

59

spandidos-publications.com

Internet Source

<1%

60

Jesús F Bermejo-Martin, Milagros González-Rivera, Raquel Almansa, Dariela Micheloud et al. "Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19", Cold Spring Harbor Laboratory, 2020

Publication

<1%

61

file.scirp.org

Internet Source

<1%

62

Hiroyuki Kato, Naohisa Kuriyama, Sergio Duarte, Pierre-Alain Clavien, Ronald W. Busuttil, Ana J. Coito. "MMP-9 deficiency shelters endothelial PECAM-1 expression and enhances regeneration of steatotic livers after ischemia and reperfusion injury", Journal of Hepatology, 2014

Publication

<1%

63

www.library.uu.nl

Internet Source

<1%

64

ajpendo.physiology.org

Internet Source

<1 %

65

L. G. Bongartz. "Transient nitric oxide reduction induces permanent cardiac systolic dysfunction and worsens kidney damage in rats with chronic kidney disease", *AJP Regulatory Integrative and Comparative Physiology*, 03/01/2010

Publication

<1 %

66

s-space.snu.ac.kr

Internet Source

<1 %

67

www.magonlinelibrary.com

Internet Source

<1 %

68

Kristina Kohl, Eva Herzog, Gerhard Dickneite, Sabine Pestel. "Evaluation of urinary biomarkers for early detection of acute kidney injury in a rat nephropathy model", *Journal of Pharmacological and Toxicological Methods*, 2020

Publication

<1 %

69

patentscope.wipo.int

Internet Source

<1 %

70

Filippo Albani, Federica Fusina, Enza Granato, Cristina Capotosto et al. "Effect of corticosteroid treatment on 1376 hospitalized COVID-19 patients. A cohort study.", Cold Spring Harbor Laboratory, 2020

<1 %

71

Uri Oron, Hana Tuby, Lidya Maltz, Orit Sagi-Assif, Ramzia Abu-Hamed, Tali Yaakobi, Keren Doenyas-Barak, Shai Efrati. "Autologous Bone-Marrow Stem Cells Stimulation Reverses Post-Ischemic-Reperfusion Kidney Injury in Rats", American Journal of Nephrology, 2014

Publication

<1%

72

Yang, J.-R., F.-H. Yao, J.-G. Zhang, Z.-Y. Ji, K.-L. Li, J. Zhan, Y.-N. Tong, L.-R. Lin, and Y.-N. He. "Ischemia/Reperfusion Induces Renal Tubule Pyroptosis via the CHOP-Caspase-11 Pathway", AJP Renal Physiology, 2013.

Publication

<1%

73

www.annualreviews.org

Internet Source

<1%

74

Yoo, Young-Chul, Kyung-Jong Yoo, Beom Jin Lim, Ji-Hae Jun, Jae-Kwang Shim, and Young-Lan Kwak. "Propofol attenuates renal ischemia-reperfusion injury aggravated by hyperglycemia", Journal of Surgical Research, 2013.

Publication

<1%

75

Baris Afsar, Patrick Rossignol, Loek van Heerebeek, Walter J. Paulus et al. "Heart failure with preserved ejection fraction: a nephrologist-directed primer", Heart Failure Reviews, 2017

<1%

76

Sandovici, M.. "Immune modulation and graft protection by gene therapy in kidney transplantation", *European Journal of Pharmacology*, 20080513

Publication

<1%

77

stemcellres.biomedcentral.com

Internet Source

<1%

78

Annual Update in Intensive Care and Emergency Medicine 2013, 2013.

Publication

<1%

79

Hussein F. Sakr, Amr M. Abbas, Ismaeel Bin-Jaliah. "Modulation of the neurological and vascular complications by grape seed extract in a rat model of spinal cord ischemia–reperfusion injury by downregulation of both osteopontin and cyclooxygenase-2", *Canadian Journal of Physiology and Pharmacology*, 2016

Publication

<1%

80

Hye Ryoung Jang, Ji Hyeon Park, Ghee Young Kwon, Jung Eun Lee et al. "Effect of preemptive treatment with human umbilical cord blood-derived mesenchymal stem cells on the development of renal ischemia-reperfusion injury in mice", *American Journal of Physiology-Renal Physiology*, 2014

Publication

<1%

81

"Spoken sessions", Thorax, 2002

Publication

<1%

82

pubs.asahq.org

Internet Source

<1%

83

Jeong, Hyeon-Uk, Ju-Hyun Kim, Dae Lee, Hyun Shim, and Hye Lee. "In Vitro Metabolic Pathways of the New Anti-Diabetic Drug Evogliptin in Human Liver Preparations", Molecules, 2015.

Publication

<1%

84

Ji Young Kim, Yuntao Bai, Laura A. Jayne, Ferdos Abdulkader et al. "SOX9 promotes stress-responsive transcription of VGF nerve growth factor inducible gene in kidney epithelial cells", Cold Spring Harbor Laboratory, 2020

Publication

<1%

85

Susan R. Rittling, David T. Denhardt. "Osteopontin Function in Pathology: Lessons from Osteopontin-Deficient Mice", Nephron Experimental Nephrology, 1999

Publication

<1%

86

D. Lamers, S. Famulla, N. Wronkowitz, S. Hartwig et al. "Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome", Diabetes, 2011

Publication

<1%

87

elpub.bib.uni-wuppertal.de

Internet Source

<1%

88

Youssef, Mahmoud I., Amr A.A. Mahmoud, and Rasha H. Abdelghany. "A new combination of sitagliptin and furosemide protects against remote myocardial injury induced by renal ischemia/reperfusion in rats", *Biochemical Pharmacology*, 2015.

Publication

<1%

89

www.pmoriano.com

Internet Source

<1%

90

A. Harmoinen, E. Ylinen, M. Ala-Houhala, M. Janas, M. Kaila, T. Kouri. "Reference intervals for cystatin C in pre- and full-term infants and children", *Pediatric Nephrology*, 2000

Publication

<1%

91

Eric D'hoore, Nathalie Neiryck, Eva Schepers, Raymond Vanholder, Francis Verbeke, Mira Van Thielen, Wim Van Biesen. "Chronic kidney disease progression is mainly associated with non-recovery of acute kidney injury", *Journal of Nephrology*, 2015

Publication

<1%

92

Tomoaki Miyazaki, Sina A. Gharib, Yun-Wei A. Hsu, Katherine Xu et al. "Cell-specific image-guided transcriptomics identifies complex

<1%

injuries caused by ischemic acute kidney injury in mice", *Communications Biology*, 2019

Publication

93

R.C. Bell, A. Hoedl, J. Turchinsky. "Fructose Feeding in the Suckling-Weaning Transition in Rats: Effects on Hyperlipidemia in Adulthood", *Archives of Physiology and Biochemistry*, 2008

Publication

<1%

94

Qianjie Wei, Jinjuan Zhao, Xingguo Zhou, Lili Yu, Zhaohui Liu, Yulin Chang. "Propofol can suppress renal ischemia-reperfusion injury through the activation of PI3K/AKT/mTOR signal pathway", *Gene*, 2019

Publication

<1%

95

Esther Peters, Andrea van Elsas, Suzanne Heemskerk, Luigi Jonk et al. "Alkaline Phosphatase as a Treatment of Sepsis-Associated Acute Kidney Injury", *Journal of Pharmacology and Experimental Therapeutics*, 2013

Publication

<1%

96

G.D. Tan, A.V. Lewis, T.J. James, P. Altmann, R.P. Taylor, J.C. Levy. "Clinical Usefulness of Cystatin C for the Estimation of Glomerular Filtration Rate in Type 1 Diabetes: Reproducibility and accuracy compared with standard measures and iohexol clearance",

<1%

Diabetes Care, 2002

Publication

97

Ravi Nistala, Virginia Savin. "Diabetes, hypertension, and chronic kidney disease progression: role of DPP4", American Journal of Physiology-Renal Physiology, 2017

Publication

<1%

Exclude quotes Off

Exclude matches < 4 words

Exclude bibliography On